[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1033
1. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ: Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev; 2005 Jul;14(7):1766-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined median survival and risk of mortality for endocrine pancreatic tumors and two types of exocrine tumors, adenocarcinomas, and mucinous tumors.
  • Survival among cases with pancreatic adenocarcinomas, mucinous tumors, and endocrine tumors were compared using Kaplan-Meier plots.
  • RESULTS: Endocrine pancreatic cancer cases had a median survival of 27 months compared with a median survival of 4 months for adenocarcinoma and mucinous tumor cases.
  • Compared with adenocarcinoma cases, endocrine tumor cases had a 0.28-fold lower risk of mortality [95% confidence interval (95% CI), 0.26-0.30], and mucinous tumor cases had a 0.88-fold lower risk (95% CI, 0.84-0.91).
  • Within histologic types, advanced tumor stage, older diagnosis age, surgery, and Black race were associated with increased risks of mortality, whereas female sex and more recent year of diagnosis were associated with decreased risks.
  • [MeSH-major] Adenocarcinoma, Mucinous / mortality. Pancreas, Exocrine / pathology. Pancreatic Neoplasms / mortality. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030115.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Borka K: [Claudin expression in different pancreatic cancers and its significance in differential diagnostics]. Magy Onkol; 2009 Sep;53(3):273-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of our studies was to compare the different CLDN expression patterns in normal pancreas cells, pancreatic endocrine tumors, adenocarcinomas, mucinous cystic tumors and acinar cell carcinomas.
  • 3.) The level of CLDN-1, -4 and -7 protein expression in borderline cystic tumors is in between that of benign and malignant tumors.
  • This supports the sequential development theory regarding mucinous cystic tumors.
  • 4.) This is a first review on childhood acinar cell carcinoma causing Cushing syndrome.
  • The adenocarcinomas and cystic mucinous tumors of exocrine origin denoted CLDN-1, -2, -4 and -7 positivity, whereas acinar cell carcinomas expressed only CLDN-1 and -2.
  • The increased CLDN-4 expression in adenocarcinomas and mucinous cystic tumors, as well as the high CLDN-3 expression in endocrine tumors may open up new prospects in the targeted therapy of these tumors. 3).
  • The claudin expression pattern of pancreas tumors may be employed in the differential diagnosis of these tumors and may be of help in deciding dignity.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Claudins / metabolism. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Claudin-1. Claudin-3. Claudin-4. Cystadenocarcinoma, Mucinous / diagnosis. Cystadenocarcinoma, Mucinous / metabolism. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Luminescence. Membrane Proteins / metabolism. Microscopy, Electron. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793693.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN2 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


3. Heinzelmann-Schwarz VA, Scolyer RA, Scurry JP, Smith AN, Gardiner-Garden M, Biankin AV, Baron-Hay S, Scott C, Ward RL, Fink D, Hacker NF, Sutherland RL, O'Brien PM: Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. J Clin Pathol; 2007 Jun;60(6):622-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries.
  • BACKGROUND: Currently, no specific immunohistochemical markers are available to differentiate primary mucinous epithelial ovarian cancer (MOC) from adenocarcinomas originating at other sites that have metastasised to the ovary, which may have an impact on patient management and prognosis.
  • AIM: To investigate the expression of two intestinal markers, galectin 4 and meprin alpha, in mucinous carcinomas of the ovary and gastrointestinal tract.
  • METHODS: Using immunohistochemical analysis, the expression of galectin 4 and meprin alpha was investigated in 10 MOCs and in 38 mucinous adenocarcinomas of colon, pancreas, stomach and appendix, the most common sites of origin of ovarian metastases.
  • RESULTS: Total cytoplasmic galectin 4 expression was relatively consistent between the different carcinomas.
  • Membranous meprin alpha expression was significantly lower in MOCs compared with gastrointestinal carcinomas.
  • Moreover, meprin alpha expression showed greater discrimination between the ovarian and gastrointestinal carcinomas than the cytokeratins CK7 and CK20, the current standard immunohistochemical markers used to determine the tissue origin of mucinous carcinomas involving the ovaries.
  • CONCLUSIONS: Meprin alpha is a useful additional marker in differentiating primary from secondary mucinous adenocarcinomas of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / metabolism. Gastrointestinal Neoplasms / pathology. Metalloendopeptidases / metabolism. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Diagnosis, Differential. Female. Galectin 4 / metabolism. Humans. Immunoenzyme Techniques. Keratin-20 / metabolism. Keratin-7 / metabolism. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):52-7 [14668551.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):41-4 [14668549.001]
  • [Cites] Glycoconj J. 2004;20(4):247-55 [15115909.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):641-3 [15166272.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1392-9 [15205684.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):876-8 [7490328.001]
  • [Cites] Eur J Biochem. 1997 Aug 15;248(1):225-30 [9310382.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1127-33 [10070973.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):617-35 [10366144.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):19-25 [15389251.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):55-60 [15722794.001]
  • [Cites] J Pathol. 2005 Apr;205(5):615-22 [15732140.001]
  • [Cites] Pathol Int. 2005 May;55(5):231-43 [15871720.001]
  • [Cites] FEBS Lett. 2005 Jun 13;579(15):3317-22 [15943977.001]
  • [Cites] Histopathology. 2005 Sep;47(3):231-47 [16115224.001]
  • [Cites] Clin Exp Metastasis. 2005;22(4):331-9 [16170669.001]
  • [Cites] Hum Pathol. 2005 Nov;36(11):1217-25 [16260276.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):3-32 [16512597.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):904-13 [16508639.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117(6):944-51 [12047147.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):40650-8 [12189145.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1849-58 [12673710.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):985-93 [12826891.001]
  • [Cites] Virchows Arch. 2003 Dec;443(6):782-6 [14576939.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • (PMID = 16822880.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 4; 0 / Keratin-20; 0 / Keratin-7; 0 / Neoplasm Proteins; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.18 / meprin A
  • [Other-IDs] NLM/ PMC1955076
  •  go-up   go-down


Advertisement
4. Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC: Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clin Cancer Res; 2005 Nov 1;11(21):7651-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas.
  • PURPOSE: Mucinous adenocarcinoma of the ovary is one of the common histologic types of ovarian cancer.
  • Its pathogenesis is largely unknown.
  • In addition, the differential diagnosis of metastatic mucinous carcinomas to the ovaries, particularly those originating from the appendix, remains challenging.
  • The purpose of this study is to identify molecular biomarkers for mucinous ovarian adenocarcinoma and compare them with those of appendiceal origin.
  • EXPERIMENTAL DESIGN: Genome-wide loss-of-heterozygosity (LOH) analysis was done on DNA isolated from 28 microdissected primary mucinous ovarian carcinomas and five appendiceal adenocarcinomas.
  • RESULTS: High levels of LOH rates (>40%) were detected on chromosome arms 9p, 17p, and 21q in mucinous ovarian carcinoma cases.
  • The frequency of allelic loss was similar between high-grade and low-grade mucinous ovarian carcinoma cases but was significantly higher in ovarian versus appendiceal cases.
  • In addition, LOH rates on five chromosomal loci were statistically different between ovarian and appendiceal carcinomas.
  • CONCLUSION: A high frequency of LOH can be found in mucinous ovarian adenocarcinomas independent of grade.
  • Despite histologic similarities between mucinous ovarian carcinomas and metastatic appendiceal carcinomas, they have distinct LOH profiles, which may be used for distinguishing the two diseases.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Appendiceal Neoplasms / genetics. Appendiceal Neoplasms / pathology. Carcinoma / genetics. Genome. Genotype. Heterozygote. Loss of Heterozygosity. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278384.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCRR NIH HHS / RR / RR33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M, Fuchs CS: Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol; 2006 Jan;19(1):59-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component.
  • Signet ring cell carcinoma and mucinous carcinoma are distinct subtypes of colorectal adenocarcinoma.
  • The morphologic and molecular spectra of colorectal carcinomas with various signet ring cell components and colorectal carcinomas with various mucinous components, compared to non-mucinous adenocarcinomas, have not been examined.
  • The study groups consisted of 39 carcinomas with various signet ring cell components ('the signet group'), 167 carcinomas with various mucinous components ('the mucinous group'), and 457 nonmucinous adenocarcinoma.
  • We visually estimated the amounts of signet ring cell and mucinous components in tumors, and subclassified the signet and mucinous groups according to the amount of each component (< or = 19, 20-49, and > or = 50%).
  • Signet ring cell carcinoma (> or = 50% signet ring cell tumors) and < or = 49% signet ring cell tumors showed similar molecular features.
  • Except for MSI and MGMT, > or = 50% mucinous tumors and < or = 49% mucinous tumors also showed similar molecular features.
  • BRAF mutations, MSI, and MLH1 loss were more frequent in both the signet and mucinous groups than nonmucinous carcinoma.
  • More frequent KRAS mutations and less frequent p16 loss and TP53 positivity were observed in the mucinous group than nonmucinous carcinoma.
  • 18q LOH and COX2 overexpression were less common in the signet group than nonmucinous carcinoma.
  • FASN levels were highest in the mucinous group, followed by nonmucinous carcinoma, and lowest in the signet group.
  • In conclusion, a minor (< or = 49%) signet ring cell or mucinous component in colorectal carcinoma suggests molecular features similar to > or = 50% signet ring cell or mucinous carcinoma, respectively.
  • Signet ring cell carcinoma and mucinous carcinoma are related subtypes of colorectal adenocarcinoma, but have molecular features distinct from each other.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16118624.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA55075-13; United States / NCI NIH HHS / CA / P01 CA87969-03
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.3.1.85 / Fatty Acid Synthases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


6. Gulwani H, Jain A: Primary papillary mucinous adenocarcinoma of the ureter mimicking genitourinary tuberculosis. Patholog Res Int; 2010;2010:738407

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary papillary mucinous adenocarcinoma of the ureter mimicking genitourinary tuberculosis.
  • Primary adenocarcinomas of the renal pelvis and ureter are rare and account for less than 1% of all malignancies at this site.
  • We report a case of primary papillary mucinous adenocarcinoma of the ureter that clinically mimicked genitourinary tuberculosis.
  • Early diagnosis is important for the better outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151719.001).
  • [ISSN] 2042-003X
  • [Journal-full-title] Pathology research international
  • [ISO-abbreviation] Patholog Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2990121
  •  go-up   go-down


7. Kendal WS, Mai KT: Histological subtypes of prostatic cancer: a comparative survival study. Can J Urol; 2010 Oct;17(5):5355-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaplan-Meier and proportional hazards analyses were performed on adenocarcinomas and five infrequent variant subtypes to determine their overall survival behavior, allowing corrections for follow up inequity, age, stage, histological grade, and year of diagnosis.
  • RESULTS: A total of 455,296 cases of prostatic cancer were reviewed, of which over 99% were conventional adenocarcinomas.
  • The remaining variants studied included ductal carcinomas (0.141%), mucinous adenocarcinomas (0.103%), small cell carcinomas (0.056%), carcinosaromas (0.07%) and embryonal carcinosarcomas (0.06%).
  • With age, stage and grade effects were corrected for in the multivariate analysis, conventional adenocarcinomas, mucinous adenocarcinomas and ductal carcinomas exhibited similar survival behavior.
  • Small cell carcinomas and carcinosarcomas exhibited poor survival, even with correction.
  • Ductal carcinomas, small cell carcinomas and both types of carcinosarcoma tended to present with metastases more frequently than conventional disease.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / pathology. Carcinosarcoma / mortality. Carcinosarcoma / pathology. Prostatic Neoplasms / mortality. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adolescent. Aged. Carcinoma, Ductal / mortality. Carcinoma, Ductal / pathology. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / pathology. Child. Humans. Kaplan-Meier Estimate. Male. Proportional Hazards Models. Retrospective Studies. SEER Program / statistics & numerical data. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20974026.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


8. Ma L, Zhang JH, Liu FR, Zhang X: [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors]. Zhonghua Zhong Liu Za Zhi; 2005 Nov;27(11):657-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
  • OBJECTIVE: To investigate hypermethylation of promoter region of RASSF1A and its relationship with ovarian malignant epithelial tumors.
  • METHODS: Methylation-specific PCR (MSP) was used to determine the hypermethylation of promoter region of ras association domain family 1 (RASSF1A) gene in 80 cases of ovarian malignant epithelial tumors.
  • Of 80 ovarian malignant epithelial tumors 42 were hypermethylated in promoter region of RASSF1A gene (52.5%).
  • There was no statistically significant difference in the frequency of hypermethylation of RASSF1A gene among serious adenocarcinomas, mucinous adenocarcinomas and endometrioid adenocarcinomas (54.2%, 52.4% and 45.5%, respectively; P > 0.05).
  • CONCLUSION: High frequency of methylation of RASSF1A promoter exists in ovarian malignant epithelial tumors as a tumor suppressor gene, its suppressor activity may be abrogated by an epigenetic mechanism.
  • Hypermethylation of RASSF1A promoter in patients with epithelial malignant ovarian tumors is related to clinical stage and histopathological grade.
  • [MeSH-minor] Carcinoma, Endometrioid / genetics. Cystadenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Serous / genetics. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438885.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


9. La Rosa S, Franzi F, Marchet S, Finzi G, Clerici M, Vigetti D, Chiaravalli AM, Sessa F, Capella C: The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. Virchows Arch; 2009 Feb;454(2):133-42
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia.
  • Acinar cell carcinoma (ACC) is a rare pancreatic cancer which may be difficult to distinguish from other solid nonadenocarcinoma tumors.
  • The diagnosis depends on the demonstration of acinar differentiation, obtained with antibodies recognizing various pancreatic enzymes that, although specific, show different sensitivity.
  • We investigated the usefulness of a C-terminal BCL10 monoclonal antibody in the diagnosis of ACCs.
  • We examined normal pancreases and different pancreatic tumors including ACCs, mixed acinar-endocrine carcinomas, ductal adenocarcinomas, mucinous, serous, solid pseudopapillary, and endocrine neoplasms.
  • In addition, various normal tissues and cases of pancreatic metaplasia of the gastroesophageal mucosa, cases of ectopic pancreas, gastrointestinal endocrine tumors, salivary and breast acinic cell carcinomas, gastric adenocarcinomas with and without acinar differentiation, and hepatocellular carcinomas were studied.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Antibodies, Monoclonal / immunology. Biomarkers, Tumor / analysis. Carcinoma, Acinar Cell / diagnosis. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19066953.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antibodies, Monoclonal; 0 / BCL10 protein, human; 0 / Biomarkers, Tumor; EC 3.1.1.1 / Carboxylesterase
  •  go-up   go-down


10. Cao D, Ji H, Ronnett BM: Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol; 2005 Jan;24(1):67-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
  • Metastatic pancreatic mucinous adenocarcinomas in the ovaries can be difficult to distinguish from primary ovarian mucinous neoplasms because the former can simulate the latter grossly and histologically and both tumor types share the same cytokeratin 7/cytokeratin 20 immunoprofile.
  • We previously reported the utility of loss of Dpc4 expression in distinguishing metastatic pancreatic carcinomas from primary ovarian mucinous tumors.
  • Recently several new pancreatic carcinoma markers have been identified, including mesothelin, fascin, and prostate stem cell antigen (PSCA).
  • In this study we investigate the expression patterns of these markers in 35 primary ovarian mucinous tumors (28 atypical proliferative [borderline] tumors and 7 invasive carcinomas) and 11 metastatic pancreatic mucinous carcinomas in the ovary.
  • Primary ovarian mucinous tumors expressed mesothelin (17%), fascin (26%), and PSCA (43%) less frequently than metastatic pancreatic adenocarcinomas (73%, 73%, and 82%, respectively).
  • Expression of all three markers was seen only in metastatic pancreatic adenocarcinomas (45%), and coexpression of at least two markers was observed significantly more frequently in metastatic (82%) than primary ovarian mucinous tumors (17%).
  • Our results indicate that an immunohistochemical panel including Dpc4, mesothelin, fascin, and PSCA is useful for evaluating difficult mucinous tumors in the ovary when the differential diagnosis includes metastatic pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / metabolism. Carrier Proteins / metabolism. Membrane Glycoproteins / metabolism. Microfilament Proteins / metabolism. Neoplasm Proteins / metabolism. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Antigens, Neoplasm. Diagnosis, Differential. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Probability

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626919.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Microfilament Proteins; 0 / Neoplasm Proteins; 0 / PSCA protein, human; 0 / mesothelin; 146808-54-0 / fascin
  •  go-up   go-down


11. Ra SH, Fishbein MC, Baruch-Oren T, Shintaku P, Apple SK, Cameron RB, Lai CK: Mucinous adenocarcinomas of the thymus: report of 2 cases and review of the literature. Am J Surg Pathol; 2007 Sep;31(9):1330-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinomas of the thymus: report of 2 cases and review of the literature.
  • BACKGROUND: Most adenocarcinomas of the mediastinum are metastatic lesions.
  • Primary thymic adenocarcinomas are extremely rare neoplasms.
  • We could find only 12 cases reported in the literature; of these 12, only 4 were of the mucinous subtype.
  • DESIGN: We report 2 additional cases of the mucinous subtype, including a previously unreported mucinous variant with numerous psammoma bodies.
  • RESULTS: The first case in a 61-year-old woman resembled a mucinous (colloid) carcinoma of other organs such as the breast and colon.
  • It consisted of islands and strips of tumor cells floating in large pools of extracellular mucin.
  • The second case in an 82-year-old woman was a mucinous adenocarcinoma arising from a thymic cyst with areas of transition from benign to dysplastic epithelium.
  • The tumor cells formed dilated glands, cords, and small nests that infiltrated the thymic cyst wall and exhibited evidence of mucin production.
  • CONCLUSIONS: Mucinous adenocarcinoma, with or without, psammoma bodies, may be of primary thymic origin and should be considered in the differential diagnosis of malignant mediastinal tumors.
  • These 2 cases provide further documentation of the rare occurrence of primary mucinous adenocarcinomas of the thymic gland.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Mediastinal Neoplasms / diagnosis. Thymus Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Antigens, CD5 / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-5. Keratin-6 / analysis. Keratin-7 / analysis. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721187.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / KRT5 protein, human; 0 / KRT7 protein, human; 0 / Keratin-5; 0 / Keratin-6; 0 / Keratin-7
  • [Number-of-references] 18
  •  go-up   go-down


12. Kalialis LV, Breiting LB, Klausen S, Dahlstrøm K: [Primary mucinous carcinoma of the skin]. Ugeskr Laeger; 2008 Oct 20;170(43):3403-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mucinous carcinoma of the skin].
  • [Transliterated title] Primaert mucinøst karcinom i huden.
  • Primary mucinous carcinoma of the skin is a rare malignant tumour originating from the sweat glands.
  • It is often misdiagnosed clinically since it has an uncharacteristic and variable presentation, and microscopically because it resembles a cutaneous metastasis from the more frequent mucinous adenocarcinomas of the colon, mammae, lungs and ovaries.
  • We present a case with regional lymph node metastases five years after excision of the primary tumour.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Head and Neck Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Middle Aged. Sweat Gland Neoplasms / pathology. Sweat Gland Neoplasms / secondary. Sweat Gland Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976594.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


13. Liang H, Ye F, Lembersky BC, Bhargava R: Correlation of WT1 expression with tumor characteristics and clinical outcomes in mucinous breast carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e22075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of WT1 expression with tumor characteristics and clinical outcomes in mucinous breast carcinoma.
  • : e22075 Background: Wilms' tumor 1(WT1) protein expression has been evaluated by immunohistochemistry (IHC) in various histologies of series of invasive breast carcinomas.
  • It is overexpressed predominantly in the mucinous subtype, in both pure and mixed mucinous carcinoma.
  • The objective of this study was to correlate WT1 expression with the clinical and biological features of mucinous breast carcinoma as well as with the clinical outcomes and management.
  • METHODS: A total of 83 cases of pure and mixed mucinous breast carcinoma diagnosed between January 1999 and May 2006 were selected from the Magee-Womens Hospital, University of Pittsburgh Medical Center pathology registry.
  • Disease free survival (DFS) was 92%.
  • Among them, WT1 expression was identified in 21/33 (64%) of pure mucinous carcinomas and 9/31 (29%) of mixed type tumors.
  • CONCLUSIONS: Overall, both pure and mixed mucinous breast carcinomas have excellent prognosis.
  • This retrospective study demonstrated that WT1 expression may be associated with favorable outcome/pathologic features for patients with mucinous breast carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963217.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Catalano V, Loupakis F, Bisonni R, Torresi U, Santini D, Silva RR, Giustini L, Falcone A, D'Emidio S, Rocchi M, Graziano F: Impact of mucinous histology on prognosis for patients with radically resected stage Dukes B2 and C colon cancer: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):4126

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of mucinous histology on prognosis for patients with radically resected stage Dukes B2 and C colon cancer: Preliminary results.
  • : 4126 Background: Previous reports have suggested that mucinous colorectal adenocarcinomas have a poorer prognosis than nonmucinous colorectal adenocarcinomas.
  • This retrospective analysis was conducted to explore whether mucinous carcinoma (MC) is associated with a worse prognosis than nonmucinous carcinoma (NMC) for patients with Dukes B2 and C radically resected colon cancer.
  • RESULTS: MC accounted for 17.9% (n=180) of all colon carcinomas.
  • No difference between MC and NMC in disease-free survival (hazard ratio, HR 1.01; 95% CI, 0.76-1.36; p=0.92) and overall survival (HR 1.05; 95% CI, 0.74-1.49; p=0.78) was found.
  • After stratification by stage of disease, MC and NMC had no statistically significant difference in 5-year disease-free survival (Dukes B2: 79.1% and 78.1%, respectively, p=0.86; Dukes C: 53.8% and 56.2%, respectively, p=0.58) and overall survival (Dukes B2: 84.2% and 85.5%, respectively, p=0.80; Dukes C: 68.0% and 67.3% p=0.52).
  • Multivariate analysis using the Cox proportional hazards model showed that the clinically significant prognostic factors were stage at diagnosis (p<0.0001), grading (p<0.0001), and number of lymph node examined (p=0.0002) in the specimen.
  • CONCLUSIONS: In this preliminary analysis, patients with mucinous histology who underwent surgery with curative intent for stage Dukes B2 and C colon cancer had similar prognosis compared to NMC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961242.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ghosn M, Hajj C, Nasr F, El Karak F, Abadjian G, Kattan J, Chahine G: Triple-negative breast cancer: Epidemiology, characteristics, and survival in a Lebanese cohort. J Clin Oncol; 2009 May 20;27(15_suppl):e22228

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathology studies showed: invasive ductal carcinoma component in 138 pts (89%), pure medullary carcinoma in 7 pts (5%), pure invasive lobular carcinoma in 6 pts (4%), pure mucinous carcinoma in 3 pts (2%) and epidermoid carcinoma in 1 pt (1%).
  • Five- year disease free survival and 5-year overall survival were respectively 75% and 88% for stage I, 58% and 72% for stage II and 40% and 63% for stage III.
  • Median survival for stage IV was 19 mths with a first line taxane-based regimen used in 50% of cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964092.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sawasaki T, Katsube Y: The Ep-CAM: A potential candidate for diagnosis in ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Ep-CAM: A potential candidate for diagnosis in ovarian cancer.
  • : e16571 Background: The purpose of this study was to examine the expression of splice variants of the Ep-CAM gene in normal ovarian epithelial tissue and ovarian carcinoma and further to associate the expression of Ep-CAM with clinicopathologic characteristics if such an association exists.
  • METHODS: Ep-CAM expression was examined by semiquantitative PCR in 122 ovarian tumors (92 adenocarcinomas, 10 low malignant potential (LMP) tumors, and 10 adenomas) and 10 normal ovaries.
  • RESULTS: In carcinomas as well as LMP tumors and adenomas, Ep-CAM mRNA expression was significantly elevated compared to that in normal ovary samples.
  • Ep-CAM mRNA expression level in carcinomas was significantly elevated compared to that in adenomas and Ep-CAM mRNA expression level in advanced clinical stage diseases was significantly higher than that in early stage diseases in ovarian carcinomas.
  • With regard to histological type, Ep-CAM mRNA expression level in mucinous adenocarcinomas was significantly higher than those in the other tissue subtypes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961514.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Berardi R, Mandolesi A, Onofri A, Maccaroni E, Mantello G, Bearzi I, Scartozzi M, Pierantoni C, Marmorale C, Cascinu S: Nuclear factor-kB (NF-kB), p53, survivin, Ki-67, and Bcl-2 as prognostic factors in locally advanced rectal cancer patients receiving radiochemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e22062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median age at diagnosis was 66 years (range 36-85).
  • Male/female ratio was 47/37; 37 patients (90%) were diagnosed with adenocarcinoma, whilst 4/41 (10%) with mucinous adenocarcinoma.
  • Moreover a high expression of Ki-67 and a low expression of bcl-2 were associated with a better TTP Conclusions: Our results suggest that NF-kB, bcl-2 and Ki-67 could represent important parameters able to predict the outcome in patients receiving neoadjuvant treatment for rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963205.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Madur B, Shet T, Chinoy R: Cytologic findings in infiltrating micropapillary carcinoma and mucinous carcinomas with micropapillary pattern. Acta Cytol; 2007 Jan-Feb;51(1):25-32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic findings in infiltrating micropapillary carcinoma and mucinous carcinomas with micropapillary pattern.
  • OBJECTIVE: To examine the observation that some mucinous carcinomas have a micropapillary pattern and are mucinous variants of the highly angioinvasive infiltrating micropapillary carcinomas (IMPC).
  • STUDY DESIGN: We evaluated cytologic findings of 13 IMPC and 55 mucinous carcinomas for comparative features.
  • RESULTS: In mucinous carcinomas, 37 of 50 (74%) had a micropapillary pattern.
  • This group included 27 cases with pure mucinous micropapillary morphology (MUMPC), 8 MUMPC associated with a ductal carcinoma of the IMPC type (MUIDC) and 2 cases of mixed mucinous carcinomas with an MUMPC and a solid variant ofpapillary carcinoma (SVPC) component.
  • On cytology both IMPC and mucinous carcinomas with micropapillary pattern demonstrated the micropapillary pattern, that is, angulated clusters or abortive papillae and ball-like clusters.
  • CONCLUSION: Although IMPC and the MUMPC share the micropapillary pattern on histologic examination, mucin alters the appearances in aspirates.
  • Recognition of this morphologic spectrum will help in understanding the behavior of these tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Carcinoma, Papillary / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / pathology. Chemotherapy, Adjuvant. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Cytol. 2007 Jan-Feb;51(1):1-2 [17328486.001]
  • (PMID = 17328491.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Martínez-Consuegra N, Baquera-Heredia J, Robles-Vidal C, Zumarán-Cuéllar O, Ortiz-Hidalgo C: [Pure mucinous (colloid) carcinoma of the male breast. An uncommon subtype]. Gac Med Mex; 2007 Jan-Feb;143(1):79-81
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pure mucinous (colloid) carcinoma of the male breast. An uncommon subtype].
  • [Transliterated title] Carcinoma mucinoso (coloide) puro de la glándula mamaria masculina. Presentación de un caso de una variante poco común.
  • Pure mucinous (colloid, mucous) carcinoma of the male breast is an extremely rare neoplasm.
  • The tumor was well demarcated, had a soft consistency with a glistening gelatinous appearance.
  • Histologically, the neoplasm corresponded to a pure mucinous carcinoma which is one of the most unusual subtYpes, accounting for less than 2% of male breast carcinomas.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Breast Neoplasms, Male / classification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388099.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


20. Saitoh M, Hayasaka T, Ohmichi M, Kurachi H, Motoyama T: Primary mucinous adenocarcinoma of the vagina: possibility of differentiating from metastatic adenocarcinomas. Pathol Int; 2005 Jun;55(6):372-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous adenocarcinoma of the vagina: possibility of differentiating from metastatic adenocarcinomas.
  • Primary vaginal adenocarcinomas are rare neoplasms.
  • Herein is reported a case of primary vaginal mucinous adenocarcinoma with an interesting mucin profile, presumably arising from a lesion of adenosis in a patient without in utero exposure to diethylstilbesterol (DES).
  • The histological features of the vaginal intramural tumor found in this patient resembled those of mucinous adenocarcinoma of the endocervical type.
  • Therefore, it was necessary to determine whether or not the tumor was metastatic from an occult cervical adenocarcinoma.
  • However, the adenocarcinoma cells of the present case did not contain sulfomucin at all, being different from most mucinous adenocarcinoma cells of the endocervical type.
  • Moreover, there were foci of adenosis adjacent to the adenocarcinoma foci, which also did not contain sulfomucin.
  • These findings indicate that the mucinous adenocarcinoma arose from vaginal adenosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Mucin 5AC. Mucin-1 / analysis. Mucin-2. Mucin-6. Mucins / analysis. Neoplasm Metastasis. Vagina / chemistry. Vagina / pathology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943796.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-6; 0 / Mucins
  •  go-up   go-down


21. Shintaku M, Kushima R, Abiko K: Colloid carcinoma of the intestinal type in the uterine cervix: mucin immunohistochemistry. Pathol Int; 2010 Feb;60(2):119-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colloid carcinoma of the intestinal type in the uterine cervix: mucin immunohistochemistry.
  • A case of colloid carcinoma (gelatinous carcinoma) of the intestinal type in the uterine cervix is reported along with the findings of an immunohistochemical study of intracytoplasmic mucus of the neoplastic cells.
  • The patient was a 69-year-old woman with a circumferential uterine cervical tumor measuring about 4 cm.
  • Histopathological examination of the hysterectomy specimen demonstrated typical features of colloid carcinoma.
  • The tumor consisted of numerous mucous nodules, and low-columnar or cuboidal cells with intracytoplasmic mucus lined the margins of the mucous nodules or floated within them.
  • Colloid carcinoma is a very rare variant of mucus-producing adenocarcinoma of the uterine cervix and probably a heterogeneous group that consists of neoplasms of different histogeneses, that is, neoplasms of endocervical, gastric, and intestinal origins.
  • Results of the immunohistochemical studies in the present case showed that neoplastic cells produced mucus of the large intestine type, thus verifying the presence of a distinct subtype of colloid carcinoma of the cervix that shows the intestinal phenotype.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Mucin-2 / biosynthesis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Humans. Hysterectomy. Immunohistochemistry. Mucin 5AC / biosynthesis. Mucin-6 / biosynthesis. Neoplasm Recurrence, Local / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398197.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucin-6
  •  go-up   go-down


22. Khunamornpong S, Suprasert P, Pojchamarnwiputh S, Na Chiangmai W, Settakorn J, Siriaunkgul S: Primary and metastatic mucinous adenocarcinomas of the ovary: Evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol; 2006 Apr;101(1):152-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary and metastatic mucinous adenocarcinomas of the ovary: Evaluation of the diagnostic approach using tumor size and laterality.
  • Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis.
  • Am J Surg Pathol 2003; 27: 985-93 [5]) that classifies mucinous adenocarcinomas of the ovary as primary when they were unilateral > or =10 cm and as metastatic when they were unilateral <10 cm or bilateral.
  • METHODS: Malignant ovarian neoplasms, which were resected in Chiang Mai University Hospital between 1992 and 2003, were histologically reviewed.
  • Mucinous adenocarcinomas involving the ovary were identified.
  • The medical records and radiologic materials were reviewed in correlation with the pathologic features to identify the primary site.
  • RESULTS: There were 74 cases of mucinous adenocarcinomas; 16 were primary ovarian; 52, metastatic; and 6 of indeterminate primary site (primary versus metastatic).
  • Primary mucinous adenocarcinomas had a mean size of 16.4 cm and bilateral involvement in 13%.
  • Metastatic mucinous adenocarcinomas had a mean size of 11.7 cm and bilateral involvement in 77%.
  • Excluding the 6 tumors of indeterminate primary site, the proposed algorithm correctly classified primary and metastatic tumors in 84% of 68 cases.
  • Of 21 unilateral mucinous adenocarcinomas > or =10 cm, 62% were primary ovarian.
  • Of 42 bilateral mucinous adenocarcinomas, 95% were metastatic.
  • CONCLUSION: The algorithm provided high accuracy in the overall prediction of primary and metastatic mucinous adenocarcinomas of the ovary, with major strength in the identification of metastatic tumors by bilaterality or size <10 cm.
  • However, the prediction of primary mucinous adenocarcinomas by unilaterality and size > or =10 cm was less reliable than previously reported.
  • Due to the overlapping features between primary and metastatic tumors and the higher frequency of the latter, the possibility of metastases should always be borne in mind in the evaluation of mucinous adenocarcinomas of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300822.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Melis M, Hernandez J, Siegel EM, McLoughlin JM, Ly QP, Nair RM, Lewis JM, Jensen EH, Alvarado MD, Coppola D, Eschrich S, Bloom GC, Yeatman TJ, Shibata D: Gene expression profiling of colorectal mucinous adenocarcinomas. Dis Colon Rectum; 2010 Jun;53(6):936-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of colorectal mucinous adenocarcinomas.
  • PURPOSE: Although mucinous adenocarcinomas represent 6% to 19% of all colorectal adenocarcinomas, little is known about the genome-wide alterations associated with this malignancy.
  • We have sought to characterize both the gene expression profiles of mucinous adenocarcinomas and their clinicopathologic features.
  • METHODS: Tumors from 171 patients with primary colorectal cancer were profiled using the Affymetrix HG-U133Plus 2.0 GeneChip with characterization of clinicopathologic data.
  • RESULTS: Twenty (11.7%) mucinous adenocarcinomas and 151 (89.3%) nonmucinous adenocarcinomas were identified.
  • Mucinous adenocarcinomas were more likely to be diagnosed with lymph node (LN) metastases (75% vs 51%, P = .04) and at a more advanced stage (85% vs 54%, P = .006) but long-term survival (5-y survival 58.9% vs 58.7%, P = NS) was similar.
  • Mucinous adenocarcinomas displayed 182 upregulated and 135 downregulated genes.
  • The most upregulated genes included those involved in cellular differentiation and mucin metabolism (eg, AQP3 + 4.6, MUC5AC +4.2, MUC2 + 2.8).
  • Altered biologic pathways included those associated with mucin substrate metabolism (P = .002 and .02), amino acid metabolism (P = .02), and the mitogen-activated protein kinase cascade (P = .02).
  • DISCUSSION: Using gene expression profiling of mucinous adenocarcinomas, we have identified the differential upregulation of genes involved in differentiation and mucin metabolism, as well as specific biologic pathways.
  • These findings suggest that mucinous adenocarcinomas represent a genetically distinct variant of colorectal adencarcinoma and have implications for the development of targeted therapies.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / genetics. Colorectal Neoplasms / genetics. Gene Expression Profiling
  • [MeSH-minor] Analysis of Variance. Aquaporin 3 / genetics. Chi-Square Distribution. Humans. Lymphatic Metastasis. Microarray Analysis. Mucin 5AC / genetics. Mucin-2 / genetics. Proportional Hazards Models. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20485009.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP3 protein, human; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 158801-98-0 / Aquaporin 3
  •  go-up   go-down


24. Xie L, Villeneuve PJ, Shaw A: Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada. Int J Oncol; 2009 Apr;34(4):1109-15
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada.
  • Previous studies have shown conflicting results on the prognosis of colorectal mucinous adenocarcinoma.
  • This study compared prognostic characteristics of patients diagnosed with mucinous and non-mucinous adenocarcinomas in a Canadian series.
  • Analyses were based on 165 colorectal mucinous and 1215 non-mucinous adenocarcinoma patients who were registered at the Ottawa Regional Cancer Centre from 1994 to 1997, with follow-up extending to December 31, 2001.
  • For colon, rectum and both combined, the distribution for age at diagnosis, stage and treatment of patients with mucinous adenocarcinoma was similar to that of non-mucinous patients (all p > or = 0.12).
  • Patients with mucinous histology had fewer well- or moderately-differentiated tumours than non-mucinous patients (all p < 0.01).
  • Overall, no statistically significant differences were noted in 5-year relative survival between mucinous and non-mucinous carcinoma for colon, rectum and their combination (p > or = 0.35 for each).
  • However, when the stages were considered separately, patients with stage III mucinous carcinoma had worse survival than patients with non-mucinous carcinoma for both sites.
  • Multivariate analysis of combined data for colon and rectal cancers indicated that independent significant prognostic factors were stage for mucinous, with age and grade as well as stage for non-mucinous carcinoma.
  • In conclusion, no significant differences in stage distribution and overall survival were found between mucinous and non-mucinous patients for colorectal cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma, Mucinous / mortality. Colorectal Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287969.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


25. Song GA, Deng G, Bell I, Kakar S, Sleisenger MH, Kim YS: Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol; 2005 Mar;26(3):745-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics.
  • We compared the frequency of CpG island methylation phenotype (CIMP), inactivation of APC, p53 and DCC genes and K-ras and BRAF mutations in 39 mucinous carcinomas (MC) and 34 non-mucinous carcinomas (NMC) of the colorectum with different microsatellite instability (MSI) status.
  • These results indicate that mucinous carcinomas of the colorectum exhibit distinct molecular genetic characteristics and may arise from distinct pathogenic pathways.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. CpG Islands

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15703832.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


26. Li D, Semba S, Wu M, Yokozaki H: Molecular pathological subclassification of mucinous adenocarcinoma of the colorectum. Pathol Int; 2005 Dec;55(12):766-74
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathological subclassification of mucinous adenocarcinoma of the colorectum.
  • The purpose of the present report was to examine the possibility of molecular pathological subtyping of mucinous adenocarcinomas (MAC) of the colorectum.
  • Genetic alterations of p53 gene and microsatellite instability (MSI) as well as immunohistochemical analysis of mucin subtypes (human gastric mucin (HGM), anti-mucin monoclonal antibody recognizing gastric gland mucous cells-1, MUC2, CD10) and expression levels of human mutL homolog 1 (hMLH1), p53 and Ki-67 were performed.
  • According to MSI and p53 status, these tumors were subclassified into three groups: mutator-type tumors with a high frequency of MSI (20%), suppressor/p53-type tumors with p53 mutation, p53 overexpression or loss of heterozygosity of D17S250 (an adjacent locus to p53; 40%) and the unclassified tumors (40%).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287491.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / Gastric Mucins; 0 / Ki-67 Antigen; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


27. Börger ME, Gosens MJ, Jeuken JW, van Kempen LC, van de Velde CJ, van Krieken JH, Nagtegaal ID: Signet ring cell differentiation in mucinous colorectal carcinoma. J Pathol; 2007 Jul;212(3):278-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet ring cell differentiation in mucinous colorectal carcinoma.
  • Approximately 10% of all colorectal carcinomas are mucinous carcinomas, characterized by extracellular mucin.
  • Occasionally, mucin accumulates intracellularly in these tumours, causing signet ring cell differentiation.
  • In this study the molecular background of signet ring cell differentiation was investigated by analysing genetic changes, changes in the expression of adhesion molecules, and mucin content.
  • Cell lines of colorectal tumours with non-mucinous (AC), mucinous (MC), and signet ring cell phenotype (MCSRC) were used for Multiplex Ligation-dependent Probe Amplification to detect deletions and amplifications in specific oncogenes and tumour suppressor genes.
  • Results were validated using a large cohort of rectal carcinomas from which clinicopathological data were available.
  • Mucinous carcinomas with signet ring cell differentiation presented at a higher T stage than adenocarcinomas and mucinous carcinomas (16% pT4 versus 3-5%, p<0.001) and were more frequently node positive (77% vs 39-44%; p<0.001).
  • In conclusion, the presence of signet ring cells in carcinomas with mucinous differentiation correlates with increased T-stage and poor prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Analysis of Variance. Cadherins / analysis. Cadherins / genetics. Cell Differentiation. Cell Line. DNA Probes / genetics. Gene Expression. Genes, bcl-2. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Mucin-2. Mucins / analysis. Mucins / genetics. Neoplasm Staging. Peptides / analysis. Peptides / genetics. RNA, Messenger / analysis. Statistics, Nonparametric. beta Catenin / analysis. beta Catenin / genetics

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 17471475.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / DNA Probes; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins; 0 / Peptides; 0 / RNA, Messenger; 0 / beta Catenin; 146046-78-8 / trefoil factor
  •  go-up   go-down


28. Zhu MH, Hu XG, Ni CR, Zhang SM, Xi PC, Yu GZ: [Mucinous noncystic (colloid) adenocarcinoma of the pancreas]. Zhonghua Bing Li Xue Za Zhi; 2005 Jul;34(7):389-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous noncystic (colloid) adenocarcinoma of the pancreas].
  • OBJECTIVE: To determine the clinicopathologic characteristics and the relationship between related gene expression and pathobiologic behavior of pancreatic mucinous noncystic adenocarcinoma.
  • METHODS: Among the 249 pancreatic carcinoma cases from the department files, 6 tumors were identified to meet the pathologic criteria of colloid carcinoma.
  • Intra- and extra- cellular mucin production were determined by AB-PAS staining.
  • Both extracellular and intracellular mucin was strongly positive for AB-PAS staining.
  • CONCLUSIONS: Pancreatic mucinous noncystic adenocarcinoma has distinct morphologic features and biologic behavior.
  • Multiple gene products including many cyclins may be involved in the pathogenesis of pancreatic colloid carcinoma.
  • The tumor has an aggressive behavior with a high frequency of invasion and metastases, though the prognosis could be better than that of ordinary ductal adenocarcinoma of pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251039.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


29. Park SY, Lee HS, Choe G, Chung JH, Kim WH: Clinicopathological characteristics, microsatellite instability, and expression of mucin core proteins and p53 in colorectal mucinous adenocarcinomas in relation to location. Virchows Arch; 2006 Jul;449(1):40-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics, microsatellite instability, and expression of mucin core proteins and p53 in colorectal mucinous adenocarcinomas in relation to location.
  • However, there have been few studies of mucinous adenocarcinoma (MA) in relation to location.
  • Therefore, we analyzed clinicopathological characteristics, microsatellite instability (MSI), and expression of MUC1, MUC2, MUC5AC mucin core proteins, and p53 by immunohistochemistry in relation to tumor location.
  • Ninety-six consecutive colorectal MAs and ninety-eight nonmucinous adenocarcinomas (nMAs) were investigated.
  • Thus, MSI-H phenotype, expression of MUC2 and MUC5AC, and infrequent p53 protein overexpression are associated with right-sided location as well as mucinous histology.
  • In univariate analysis, right-sided location had a favorable effect on disease specific survival of the patients with MA, although it is not an independent predictor of survival.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Chromosomal Instability / genetics. Colorectal Neoplasms / genetics. Mucins / biosynthesis. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645863.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


30. Maksimović S: [Survival rates of patients with mucinous adenocarcinoma of the colorectum]. Med Arh; 2007;61(1):26-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival rates of patients with mucinous adenocarcinoma of the colorectum].
  • PURPOSE: Mucinous adenocarcinoma is one of the histological subtypes of colorectal cancer.
  • Mucinous colorectal adenocarcinomas comprise approximately 1 to 6 percent of all colorectal epithelial cancers.
  • Frequently are more advanced at diagnosis and have a poorer prognosis than nonmucinous colorectal adenocarcinomas.
  • 39 patients had mucinous colorectal adenocarcinomas.
  • 368 patients had nonmucinous colorectal adenocarcinomas.
  • To determine whether the mucinous adenocarcinoma itself was independent prognostic factor in the curative resected patients, a multivariate analysis was performed.
  • RESULTS: The mucinous adenocarcinoma patients compared to patients with nonmucinous adenocarcinoma patients were found to be younger (p= 0,001), have more lymph node metastases (46,15% vs. 38,31%, p=0,0053), more peritoneal dissemination (20,51% vs. 5,1%, p <0,0001), greater frequency of advanced stage disease (p= 0,0006), lower rate of curative resection (76,3% vs. 84,9%, p=0,0045), and lower overall 5-year survival rates (39% vs. 60,3%, p=0,0002.
  • DISCUSSION: Conflicting results are found in the published literature regarding the relationship between mucinous colorectal cancer and survival.
  • Although the weight of the published literature suggests that mucinous adenocarcinoma is associated with poorer outcome, contradictory reports suggest that the clinical relevance of this histological type in this patient population remains unclear The lack of consensus may be attributable to the limited detection power inherent in studies that test small subsets of patients and the diversity inherent in the inclusion of patients with all Dukes' stages in the analysis.
  • Indeed, these series studied prognosis from initial diagnosis, generally in patients treated with surgery alone, and did not specifically address outcomes in patients treated with chemotherapy.
  • Therefore, published data on the responsiveness of mucinous CRC to chemotherapy are lacking.
  • Mucinous tumors were associated with a higher proportion of patients with nodal metastases and peritoneal metastases, while the most common site of metastases for patients with non-mucinous histology was the liver.
  • A higher proportion of peritoneal metastases in patients with mucinous CRC were also reported in previous studies.
  • Conversely, in the present study, the other main characteristics of patients, such age, performance status, primary tumor side, baseline CEA level and number of metastasis sites, were comparable in cases and controls.
  • CONCLUSIONS: The mucinous histological type itself was an independent factor for poor prognosis for patients who underwent curative surgery.
  • [MeSH-major] Adenocarcinoma, Mucinous / mortality. Colorectal Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582971.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Bosnia and Herzegovina
  • [Number-of-references] 25
  •  go-up   go-down


31. Park KJ, Bramlage MP, Ellenson LH, Pirog EC: Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation. Appl Immunohistochem Mol Morphol; 2009 Jan;17(1):8-11
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation.
  • Primary mucinous tumors of the female genital tract have morphologic features similar to primary gastrointestinal adenocarcinomas, and distinguishing these malignancies may be extremely difficult.
  • The purpose of this study was to characterize the immunostaining patterns of tumors of the female genital tract that show mucinous differentiation using cytokeratin 7 (CK7), CK20, and CDX2 and to evaluate the usefulness of these markers in differentiating these tumors from gastrointestinal tract adenocarcinomas and also from each other.
  • A total of 64 cases were collected, including adenocarcinomas of the ovary (n=13), endocervix (n=16), endometrium (n=34), and vagina (n=1), all of which showed predominant mucinous differentiation.
  • Intestinal mucinous differentiation was present in 11 of the cases (6 endocervical, 4 ovarian, and 1 vaginal adenocarcinoma).
  • However, 25% of endocervical, 24% of ovarian, and 3% of endometrial adenocarcinomas were positive for CDX2, CK20, or both.
  • The positivity for CDX2 and CK20 correlated with intestinal differentiation: 73% of all intestinal mucinous adenocarcinomas and 4% of all Müllerian mucinous adenocarcinomas showed positivity for the hindgut markers.
  • In conclusion, immunostaining for CK7/CK20/CDX2 is helpful in distinguishing Müllerian subtype of mucinous gynecologic tumors from lower gastrointestinal tract malignancies.
  • In gynecologic mucinous tumors with intestinal differentiation, the overlap of staining positivity may be a limiting factor.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18776815.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Neoplasm Proteins
  •  go-up   go-down


32. Shet T, Chinoy R: Presence of a micropapillary pattern in mucinous carcinomas of the breast and its impact on the clinical behavior. Breast J; 2008 Sep-Oct;14(5):412-20
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of a micropapillary pattern in mucinous carcinomas of the breast and its impact on the clinical behavior.
  • Infiltrating micropapillary carcinomas (IMPC) of breast are highly angioinvasive tumors with poor prognosis.
  • This study is based on the observation that a similar micropapillary pattern is also observed in mucinous carcinomas of breast.
  • About 102 mucinous carcinomas were evaluated for the presence and impact of this micropapillary pattern on the clinical behavior.
  • Of these, 68 were mucinous carcinomas with a micropapillary pattern (MUMPC), 20 had MUMPC mixed with an infiltrating duct carcinoma component, two were solid variants of papillary carcinoma with mucin (SVPCMU), five had collision of the MUMPC and SVPCMU patterns and seven were mucinous carcinomas with signet ring cells (MUS).
  • The factors negatively affecting overall survival (OAS) and disease-free survival (DFS) included the histological type of mucinous carcinoma, nodal metastases, an irregular tumor border, <50% mucin and an IMPC type of local recurrence or metastases.
  • In the multivariate analysis, the histologic type of mucinous carcinoma and an irregular tumor border were most significant for OAS and DFS.
  • Thus, 86% of mucinous carcinomas in this study were mucinous variants of the angioinvasive infiltrating micropapillary carcinomas.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Breast Neoplasms / pathology. Carcinoma, Papillary / secondary. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Biopsy, Needle. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673338.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. King-Yin Lam A, Ong K, Ho YH: Colorectal mucinous adenocarcinoma: the clinicopathologic features and significance of p16 and p53 expression. Dis Colon Rectum; 2006 Sep;49(9):1275-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal mucinous adenocarcinoma: the clinicopathologic features and significance of p16 and p53 expression.
  • PURPOSE: This study was designed to examine the clinicopathologic features and p53 and p16 expressions in colorectal mucinous adenocarcinoma and colorectal signet-ring cell carcinoma.
  • METHODS: The clinicopathologic features of 36 patients with colorectal mucinous adenocarcinoma and colorectal signet-ring cell carcinoma were analyzed and compared with 228 patients with colorectal adenocarcinomas.
  • The p53 and p16 expressions in the colorectal mucinous adenocarcinoma and colorectal signet-ring cell carcinoma were studied by immunohistochemistry.
  • RESULTS: Colorectal mucinous adenocarcinoma and colorectal signet-ring cell carcinoma accounted for 14 percent of colorectal cancer.
  • Fifty-six percent of the carcinomas were located in the proximal colorectum, most commonly in the transverse colon.
  • Compared with the usual colorectal adenocarcinoma, colorectal mucinous adenocarcinoma and colorectal signet-ring cell carcinoma was found more often in proximal colorectum (P = 0.002), larger (P = 0.05), and in advanced stages (P = 0.018).
  • Forty-four percent (n = 16) of the colorectal mucinous adenocarcinoma and colorectal signet-ring cell carcinoma showed p53 expression.
  • All the patients with colorectal mucinous adenocarcinoma and colorectal signet-ring cell carcinoma with a positive family history of colorectal adenocarcinoma had tumors that showed p53 expression (P = 0.012).
  • The survival of these patients with colorectal mucinous adenocarcinoma and colorectal signet-ring cell carcinoma was poorer if the lesions were of advanced stages (P = 0.023) or with family history of colorectal cancer (P = 0.0015).
  • Also, patients with colorectal mucinous adenocarcinoma and colorectal signet-ring cell carcinoma that did not express p16 and p53 had better survival than other patients (P = 0.04).
  • CONCLUSIONS: Colorectal mucinous adenocarcinoma and colorectal signet-ring cell carcinoma had distinctive clinicopathologic features.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Carcinoma, Signet Ring Cell / genetics. Colorectal Neoplasms / genetics. Gene Expression. Genes, p16. Genes, p53

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912910.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


34. Levy G, Finkelstein A, McNiff JM: Immunohistochemical techniques to compare primary vs. metastatic mucinous carcinoma of the skin. J Cutan Pathol; 2010 Apr;37(4):411-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical techniques to compare primary vs. metastatic mucinous carcinoma of the skin.
  • BACKGROUND: Primary and metastatic mucinous carcinomas in skin are histologically indistinguishable.
  • Immunohistochemical panels help differentiate primary and metastatic adenocarcinoma of skin, but data regarding mucinous carcinoma is scant.
  • METHODS: We stained five primary mucinous carcinomas, two mucinous carcinomas metastatic to skin and five primary breast and colon mucinous carcinomas with p63, CD15, CK5/6, CK7, CK20, calponin and D2-40 to identify patterns that might differentiate primary from metastatic disease.
  • RESULTS: All cases of primary mucinous carcinoma of the skin were positive for CK7, 40% showed rare cells labeled for p63 and 20% of cases labeled focally for CK5/6.
  • The breast mucinous carcinomas metastatic to the skin were negative for all markers except CK7, although 60% of primary breast carcinomas labeled for p63.
  • Colon mucinous carcinoma labeled only for CK20.
  • CONCLUSIONS: In a small subset of mucinous carcinomas (20% in this series), positive labeling for CK5/6 indicated primary cutaneous tumor.
  • Staining with p63 also favored primary over metastatic disease.
  • Myoepithelial cell layers were not consistently identified to enable the identification of primary disease.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Biomarkers, Tumor / metabolism. Immunohistochemistry / methods. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / pathology. Diagnosis, Differential. Female. Head and Neck Neoplasms / pathology. Humans. Male. Middle Aged. Scalp

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788442.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Liu X, Germin BI, Zhong J, Ekholm S: N-Acetyl peak in MR spectra of intracranial metastatic mucinous adenocarcinomas. Magn Reson Imaging; 2010 Nov;28(9):1390-4
Hazardous Substances Data Bank. (L)-ASPARTIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-Acetyl peak in MR spectra of intracranial metastatic mucinous adenocarcinomas.
  • We report two cases of histopathology-confirmed intracranial metastatic mucinous adenocarcinoma, which predominantly showed a large metabolite peak at 2.0 ppm, mimicking an NAA peak of normal brain tissue.
  • This finding could be of help in the interpretation of MRS in cases of intracranial enhancing mass lesions, metastases or gliomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Aspartic Acid / analogs & derivatives. Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Spectroscopy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20797831.001).
  • [ISSN] 1873-5894
  • [Journal-full-title] Magnetic resonance imaging
  • [ISO-abbreviation] Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glycoproteins; 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate
  •  go-up   go-down


36. Ren FY, Shao CW, Zuo CJ, Lu JP: CT features of colloid carcinomas of the pancreas. Chin Med J (Engl); 2010 May 20;123(10):1329-32
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT features of colloid carcinomas of the pancreas.
  • BACKGROUND: Colloid carcinomas of the pancreas have better prognosis than ordinary ductal adenocarcinoma, and preoperative distinction of colloid carcinoma from other pancreatic tumors is valuable for patient therapeutic planning and prognosis assessment.
  • However, data about CT features of colloid carcinoma are very limited.
  • Seven patients with pathologically proven colloid carcinoma of the pancreas were included.
  • CONCLUSIONS: Colloid carcinomas of the pancreas appear as round or labular masses with great percent of cystic areas and slight hyp-attenuation on unenhanced CT and peripheral and internal meshlike progressive delayed enhancement on enhanced CT.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20529590.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


37. Kim DH, Kim JW, Cho JH, Baek SH, Kakar S, Kim GE, Sleisenger MH, Kim YS: Expression of mucin core proteins, trefoil factors, APC and p21 in subsets of colorectal polyps and cancers suggests a distinct pathway of pathogenesis of mucinous carcinoma of the colorectum. Int J Oncol; 2005 Oct;27(4):957-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mucin core proteins, trefoil factors, APC and p21 in subsets of colorectal polyps and cancers suggests a distinct pathway of pathogenesis of mucinous carcinoma of the colorectum.
  • Mucin core proteins are expressed in a tissue and cell type specific manner in the normal gastrointestinal tract.
  • Aberrant expression of mucin core proteins have been reported in colorectal neoplasms.
  • To examine the relationship between subsets of colorectal polyps and non-mucinous and mucinous adenocarcinomas of the colorectum, we evaluated the frequency of the expression of cell lineage associated mucin core proteins (MUC5AC and MUC2), trefoil factors (TFF1 and TFF3), and APC and p21 in these tissues.
  • An immunohistochemical study was performed in 10 normal rectal mucosa samples (NM) 21 hyperplastic polyps (HP), 20 serrated adenomas (SA), 25 tubular adenomas (TA), 13 tubulovillous adenomas (TVA), 7 villous adenomas (VA), 42 non-mucinous colorectal cancers (NMC), and 19 mucinous colorectal cancers (MC).
  • A higher frequency of ectopic expression of gastric foveolar mucin, MUC5AC, and the expression of intestinal goblet cell mucins, MUC2, was observed respectively in HP (100%, 100%), SA (85%, 85%), TVA (85%, 85%), and VA (100%, 100%), compared to TA (32%, p<0.002; 36%, p<0.01).
  • Our results showed that MUC2 expression and de novo ectopic expression of MUC5AC and TFF1 are more frequent in HP, SA, TVA, VA, and MC than in TA and NMC.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Adenomatous Polyposis Coli Protein / biosynthesis. Colorectal Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Mucins / chemistry. Peptides / metabolism. Proto-Oncogene Proteins p21(ras) / biosynthesis. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adenoma / metabolism. Cell Differentiation. Cell Line, Tumor. Cell Lineage. Cell Nucleus / metabolism. Cytoplasm / metabolism. Humans. Immunohistochemistry. Mucin 5AC. Mucin-2

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142311.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucins; 0 / Peptides; 0 / TFF1 protein, human; 0 / TFF3 protein, human; 0 / Tumor Suppressor Proteins; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  •  go-up   go-down


38. Bal A, Joshi K, Sharma SC, Das A, Verma A, Wig JD: Prognostic significance of micropapillary pattern in pure mucinous carcinoma of the breast. Int J Surg Pathol; 2008 Jul;16(3):251-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of micropapillary pattern in pure mucinous carcinoma of the breast.
  • Breast carcinoma with micropapillary architecture is associated with aggressive behavior.
  • Similar micropapillary pattern in pure mucinous carcinoma has been noticed and has been shown to convey poor prognosis.
  • In this study 17 cases of pure mucinous carcinoma of the breast seen during a 10-year period have been reviewed, with special reference to micropapillary pattern.
  • Diffuse micropapillary pattern was seen in 6 of 17 cases of mucinous carcinoma of the breast and demonstrated reverse polarity immunostaining pattern with "Epithelial Membrane Antigen."
  • In this present study, mucinous carcinomas with micropapillary pattern showed a low nuclear grade, higher incidence of hormone receptor positivity, and lower incidence of Her-2/neu similar to mucinous carcinomas without micropapillary pattern, thus explaining their indolent behavior.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387988.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


39. Lacroix-Triki M, Lambros MB, Geyer FC, Suarez PH, Reis-Filho JS, Weigelt B: Absence of microsatellite instability in mucinous carcinomas of the breast. Int J Clin Exp Pathol; 2010 Nov 27;4(1):22-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of microsatellite instability in mucinous carcinomas of the breast.
  • In these anatomical sites, MSI-high carcinomas often display a mucinous histology.
  • The aim of this study was to determine whether mucinous carcinomas of the breast would more frequently display MSI-high than invasive ductal carcinomas of no special type (IDC-NSTs).
  • MSH2, MSH6, MLH1 and PMS2) was immunohistochemically assessed in 35 mucinous breast carcinomas and 35 histological grade- and oestrogen receptor (ER) status-matched IDC-NSTs, and in a series of 245 invasive breast cancers.
  • Nine mucinous carcinomas were microdissected and subjected to MSI analysis by PCR using the MSI markers BAT26 and BAT40.
  • No immunohistochemical evidence of MSI-high was found in the 35 mucinous carcinomas and 35 grade- and ER-matched IDC-NSTs, and in the cohort of 245 invasive breast cancers.
  • In addition, no evidence of MSI-high was observed by PCR analysis using the BAT26 and BAT40 markers in the nine mucinous carcinomas tested.
  • Our results demonstrate that MSI-high phenotype is remarkably rare in invasive breast cancer, and that, in contrast to mucinous carcinomas of other anatomical sites, MSI is not a common event in mucinous carcinomas of the breast.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2000 Feb;117(1):61-5 [10700869.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):580-2 [14520695.001]
  • [Cites] J Pathol. 2003 Nov;201(3):389-94 [14595750.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):839-44 [10213220.001]
  • [Cites] Mutat Res. 2004 Dec 21;568(2):275-82 [15542114.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8541-9 [15574760.001]
  • [Cites] J Pathol. 2005 Jan;205(2):248-54 [15641021.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):1046-52 [16175185.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 7;99(3):244-52 [17284719.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):417-26 [17325484.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2323-8 [17438090.001]
  • [Cites] Am J Surg. 2007 Oct;194(4):527-31 [17826073.001]
  • [Cites] Hum Pathol. 2008 Jan;39(1):116-25 [17949789.001]
  • [Cites] Carcinogenesis. 2008 Feb;29(2):434-9 [18048385.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):513-23 [18223478.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):293-300 [18556767.001]
  • [Cites] J Pathol. 2008 Aug;215(4):398-410 [18484683.001]
  • [Cites] Breast Cancer Res Treat. 2008 Oct;111(3):541-7 [18026874.001]
  • [Cites] J Pathol. 2008 Oct;216(2):141-50 [18720457.001]
  • [Cites] Oncogene. 2008 Sep 11;27(40):5359-72 [18490921.001]
  • [Cites] Am J Surg. 2008 Oct;196(4):549-51 [18809061.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6847-54 [18980979.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3208-15 [18990764.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5783-8 [18809606.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Apr;48(4):351-65 [19156836.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):790-800 [19228622.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2711-22 [19318498.001]
  • [Cites] J Pathol. 2009 Jul;218(3):301-15 [19479727.001]
  • [Cites] Clin Genet. 2009 Jul;76(1):1-18 [19659756.001]
  • [Cites] Mod Pathol. 2009 Nov;22(11):1401-14 [19633645.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Dec;6(12):718-30 [19942925.001]
  • [Cites] J Pathol. 2010 Jan;220(2):263-80 [19927298.001]
  • [Cites] Lancet Oncol. 2010 Apr;11(4):339-49 [20181526.001]
  • [Cites] Gastroenterology. 2010 Jun;138(6):2073-2087.e3 [20420947.001]
  • [Cites] Histopathology. 2010 Aug;57(2):171-92 [20500230.001]
  • [Cites] Sci Transl Med. 2010 Sep 1;2(47):47ps43 [20811040.001]
  • [Cites] J Pathol. 2010 Nov;222(3):282-98 [20815046.001]
  • [Cites] Mod Pathol. 2010 Oct;23(10):1334-45 [20543821.001]
  • [Cites] PLoS One. 2010;5(10):e13314 [20967208.001]
  • [Cites] Breast Cancer Res Treat. 2010 Dec;124(3):653-66 [20213079.001]
  • [Cites] Eur J Cancer. 2011 Jan;47(1):138-50 [20832293.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):696-700 [15017435.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5853-5 [8261393.001]
  • [Cites] Int J Cancer. 1996 Nov 15;68(4):447-51 [8945614.001]
  • [Cites] Int J Cancer. 1997 Mar 4;70(5):499-501 [9052745.001]
  • [Cites] J Pathol. 1997 Aug;182(4):380-4 [9306957.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Feb;21(2):101-7 [9491320.001]
  • [Cites] J Pathol. 2002 May;197(1):6-13 [12081205.001]
  • (PMID = 21228925.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC3016101
  • [Keywords] NOTNLM ; Mucinous carcinoma / breast cancer / genetics / immunohistochemistry / microsatellite instability / mismatch repair
  •  go-up   go-down


40. Maeda D, Ota S, Ikeda S, Kawano R, Hata E, Nakajima J, Mori M, Fukayama M: Mucinous adenocarcinoma of the thymus: a distinct variant of thymic carcinoma. Lung Cancer; 2009 Apr;64(1):22-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of the thymus: a distinct variant of thymic carcinoma.
  • BACKGROUND: Primary thymic mucinous adenocarcinoma is a recently described subtype of thymic carcinoma, which behaves aggressively.
  • METHODS: The authors analyzed the clinical and pathological findings of three cases of thymic mucinous adenocarcinoma, and reviewed five cases previously reported in the English literature.
  • Areas with a gelatinous appearance were present.
  • Histologically, all of the tumors were adenocarcinomas with abundant mucin production, which resembled the mucinous adenocarcinomas of other organs.
  • Malignant tumor cells in nests, tubules and cribriform structures floated in pools of extracellular mucin.
  • The cyst wall was partially lined by malignant mucinous epithelium, which showed transition from benign thymic epithelium.
  • CONCLUSION: Growing evidence suggests that mucinous adenocarcinoma is a distinct morphological variant of primary thymic carcinoma.
  • We believe that clinicians and surgical pathologists should include thymic mucinous adenocarcinoma in the differential diagnosis of mediastinal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Thymoma / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunoenzyme Techniques. Keratin-20 / metabolism. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18722686.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-20
  •  go-up   go-down


41. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miller DM: HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer; 2009;9:433
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.
  • BACKGROUND: The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is low, prompting interest in targeted molecular therapies.
  • METHODS: HER2 status was tested in 33 mucinous carcinomas and 16 mucinous borderline ovarian tumors (BOT)).
  • Three prospectively identified recurrent mucinous ovarian carcinomas were assessed for HER2 amplification and patients received trastuzumab therapy with conventional chemotherapy.
  • RESULTS: Amplification of HER2 was observed in 6/33 (18.2%) mucinous carcinomas and 3/16 (18.8%) BOT.
  • HER2 amplification in primary mucinous carcinomas was not associated with an increased likelihood of recurrence.
  • The prospectively identified recurrent mucinous carcinomas showed overexpression and amplification of HER2; one patient's tumor responded dramatically to trastuzumab in combination with conventional chemotherapy, while another patient experienced an isolated central nervous system recurrence after trastuzumab therapy.
  • CONCLUSION: HER2 amplification is relatively common in ovarian mucinous carcinomas (6/33, 18.2%), although not of prognostic significance.
  • Trastuzumab therapy is a treatment option for patients with mucinous carcinoma when the tumor has HER2 amplification and overexpression.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / genetics. Antibodies, Monoclonal / therapeutic use. Gene Amplification. Genes, erbB-2. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3651-64 [11054438.001]
  • [Cites] Int J Gynecol Pathol. 2010 Mar;29(2):99-107 [20173494.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):283-90 [12525520.001]
  • [Cites] APMIS. 2003 Mar;111(3):444-50 [12752225.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):104-12 [14679128.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):887-95 [14984957.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):200-5 [15213595.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1813-21 [7538656.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Clin Ther. 1999 Feb;21(2):309-18 [10211534.001]
  • [Cites] Semin Oncol. 1999 Aug;26(4 Suppl 12):71-7 [10482196.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):570-5 [15581965.001]
  • [Cites] Int J Gynecol Pathol. 2005 Apr;24(2):147-52 [15782071.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):436-41 [15863142.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jul;24(3):205-17 [15968194.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):681-5 [16077916.001]
  • [Cites] Am J Pathol. 2005 Oct;167(4):913-20 [16192626.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1772-7 [16150805.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] Am J Clin Pathol. 2006 Jul;126(1):101-9 [16753589.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1421-8 [16980943.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2 Suppl 1):S23-5 [17027068.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):120-9 [17143264.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):192-8 [17361205.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):795-805 [17031648.001]
  • [Cites] J Mol Histol. 2007 May;38(2):151-7 [17216303.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] Int J Oncol. 2008 Jan;32(1):89-95 [18097546.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):161-74 [18317227.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1239-51 [18602670.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e22 [18671886.001]
  • [Cites] BMC Cancer. 2008;8:252 [18761742.001]
  • [Cites] J Natl Cancer Inst. 2009 May 20;101(10):736-50 [19436038.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):391-400 [12352188.001]
  • (PMID = 20003286.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ PMC2803495
  •  go-up   go-down


42. Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, Beheshti J, Chirieac LR, Mark EJ, Iafrate AJ: Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn; 2007 Jul;9(3):320-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
  • Somatic mutations in the epidermal growth factor receptor gene (EGFR) are detected in a subset of lung adenocarcinomas, particularly bronchioloalveolar carcinoma (BAC) and adenocarcinoma with bronchioloalveolar features (AWBF), and correlate with clinical response to tyrosine kinase inhibitors (TKIs).
  • In contrast, lung adenocarcinomas refractory to TKIs often have activating mutations in KRAS but lack EGFR mutations.
  • Some adenocarcinomas have mucinous histology, but the clinical and molecular significance of the mucinous pattern is less well studied.
  • EGFR mutations were detected in 14 of 30 (47%) nonmucinous tumors, whereas 0 of 13 mucinous tumors harbored an EGFR mutation (P = 0.003).
  • Missense mutations in KRAS codon 12 were detected in six of seven (86%) mucinous adenocarcinomas but only 3 of 18 (17%) nonmucinous adenocarcinomas (P = 0.003).
  • Thus, in BAC/AWBF mucinous differentiation was significantly correlated with the absence of EGFR mutation and presence of KRAS mutation, suggesting that mucinous BACs/AWBFs are unlikely to respond to TKIs.
  • Therefore, our data suggest that EGFR sequence analysis could be avoided in BAC/AWBF when true mucinous morphology is identified, avoiding the associated testing costs.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Genes, erbB-1. Genes, ras. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Mutation
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Differentiation / genetics. DNA Mutational Analysis. Disease Progression. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6816-22 [16203769.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8081-92 [16204011.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1647-53 [16533793.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2538-44 [16638863.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4403s-4408s [16857818.001]
  • [Cites] Oncologist. 2007 Jan;12(1):90-8 [17285735.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):587-95 [17290067.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1525-30 [11745231.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3798-807 [12953099.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Am Rev Respir Dis. 1990 Dec;142(6 Pt 2):S27-30 [2252272.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2377-86 [8708731.001]
  • [Cites] J Pathol. 1996 Jul;179(3):254-9 [8774479.001]
  • [Cites] Adv Intern Med. 1960;10:329-58 [13762021.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2493-501 [15710947.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2556-68 [15767641.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3279-87 [15886315.001]
  • [Cites] Virchows Arch. 2005 May;446(5):483-8 [15815931.001]
  • [Cites] PLoS Med. 2005 Jan;2(1):e17 [15696205.001]
  • [Cites] Chest. 2005 Jul;128(1):317-21 [16002952.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):133-44 [16014883.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):355-63 [16052218.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5878-85 [16115929.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2296-302 [16214908.001]
  • (PMID = 17591931.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1899415
  •  go-up   go-down


43. Türüt H, Demirag F, Gulhan E, Tastepe I: Primary pulmonary mucinous adenocarcinoma in a 15-year-old boy. Eur J Cardiothorac Surg; 2006 May;29(5):851-3
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary mucinous adenocarcinoma in a 15-year-old boy.
  • Bronchogenic carcinomas are rare in childhood.
  • Furthermore, mucinous (so-called colloid) adenocarcinoma, an unusual variant of pulmonary adenocarcinoma, is extremely rare in the first decade of life.
  • To the best of our knowledge, we report the first case with primary pulmonary mucinous adenocarcinoma at the age of 15.
  • Another interesting aspect of this tumor was its metastasis to thyroid, because metastasis of primary bronchogenic carcinomas to thyroid is uncommon.
  • One can face up with difficulties in the establishment of the definite diagnosis due to its complex and often indistinguishable histopathologic pattern.
  • In this paper we report a patient with pulmonary solid mass and thyroid nodule, initially diagnosed as metastatic thyroid carcinoma in whom postoperative resective surgery confirmed primary pulmonary mucinous adenocarcinoma with synchronous metastasis to thyroid.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / secondary. Lung Neoplasms / diagnosis. Thyroid Neoplasms / secondary
  • [MeSH-minor] Adolescent. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520054.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Kapur P, Rakheja D, Bastasch M, Molberg KH, Sarode VR: Primary mucinous adenocarcinoma of the thymus: a case report and review of the literature. Arch Pathol Lab Med; 2006 Feb;130(2):201-4
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous adenocarcinoma of the thymus: a case report and review of the literature.
  • Primary thymic mucinous adenocarcinoma is extremely rare; to our knowledge, only 2 cases have been reported to date.
  • We describe a third case of primary mucinous adenocarcinoma of the thymus in a 41-year-old man who presented with an anterior mediastinal mass with subsequent metastasis to the lung.
  • The initial diagnosis was of metastatic mucinous adenocarcinoma, but extensive clinical workup of the patient failed to reveal a primary tumor elsewhere in the body.
  • The specific identification of mucinous adenocarcinoma as a primary thymic neoplasm can be difficult or impossible.
  • Morphologic and immunophenotypic similarities to mucinous adenocarcinomas of the gastrointestinal tract can pose diagnostic challenges for surgical pathologists, especially in small biopsy specimens.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Thymus Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Combined Modality Therapy. Disease-Free Survival. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454563.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


45. Kazama Y, Watanabe T, Kanazawa T, Tada T, Tanaka J, Nagawa H: Mucinous carcinomas of the colon and rectum show higher rates of microsatellite instability and lower rates of chromosomal instability: a study matched for T classification and tumor location. Cancer; 2005 May 15;103(10):2023-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinomas of the colon and rectum show higher rates of microsatellite instability and lower rates of chromosomal instability: a study matched for T classification and tumor location.
  • BACKGROUND: The clinicopathologic significance of mucinous carcinomas (Muc) of the colon and rectum has been widely discussed, but there have been few studies on Muc regarding genetic and epigenetic alterations.
  • The current study analyzed genetic and epigenetic alterations of Muc to clarify their differences from well differentiated adenocarcinomas (WD).
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Chromosomal Instability / genetics. Colonic Neoplasms / genetics. Microsatellite Repeats / genetics. Rectal Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812832.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


46. Albores-Saavedra J, Galliani C, Chable-Montero F, Batich K, Henson DE: Mucin-containing Rokitansky-Aschoff sinuses with extracellular mucin deposits simulating mucinous carcinoma of the gallbladder. Am J Surg Pathol; 2009 Nov;33(11):1633-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin-containing Rokitansky-Aschoff sinuses with extracellular mucin deposits simulating mucinous carcinoma of the gallbladder.
  • We report here 5 cases of mucin-containing R-As that ruptured, and as a result, extracellular mucin escaped into the adjacent stroma.
  • They were compared with 10 mucinous carcinomas of the gallbladder.
  • Three cases of mucin-containing R-As accompanied by abundant extracellular mucin deposits with epithelial strips, glands and papillary structures were misinterpreted as mucinous carcinomas.
  • In the remaining 2 cases, the extracellular mucin associated with R-As was acellular and regarded as focal.
  • The youngest patient was a 2-year-old boy in whom the mucin-containing R-As were discovered incidentally by magnetic resonance imaging.
  • The R-As located in the lamina propria contained mucin but were not cystically dilated whereas those located in the subserosa were mucin-filled and often cystically dilated.
  • Detached fragments of biliary epithelium, small glands, and papillary structures lacking cytologic atypia and mitotic figures were identified in the abundant mucin deposits located in the subserosa of 3 cases.
  • Clues to separate mucin-containing R-As from mucinous carcinoma are provided.
  • All 5 patients with mucin-containing R-As are disease free 8 months to 7 years after surgery (median follow-up of 39 mo).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Gallbladder / pathology. Gallbladder Neoplasms / pathology. Mucins / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Cell Proliferation. Child, Preschool. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucous Membrane / metabolism. Mucous Membrane / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2011 Jan;35(1):153-4 [21164300.001]
  • (PMID = 19738458.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


47. Shah VB, Amonkar GP, Deshpande JR, Bhalekar H: Mucinous adenocarcinoma of the renal pelvis with pseudomyxoma peritonei. Indian J Pathol Microbiol; 2008 Oct-Dec;51(4):536-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of the renal pelvis with pseudomyxoma peritonei.
  • Mucinous adenocarcinoma of the renal pelvis is an extremely rare tumor with very few case reports in literature.
  • Pseudomyxoma peritonei is an uncommon condition characterized by the presence of mucinous gelatinous material in the peritoneal cavity.
  • It occurs secondary to primary mucinous neoplasms of particularly the appendix and the ovary.
  • Grossly, the entire kidney was converted into a cystic mass measuring 15x15x12 cm containing gelatinous mucinous material weighing 1 kg.
  • Histologically, the tumor was composed of simple and complex glandular acini together with a superficial resemblance to colonic mucosa with abundant extracellular mucin.
  • Thus, a diagnosis of mucinous adenocarcinoma of the renal pelvis leading to pseudomyxoma peritonei was made.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Neoplasms, Multiple Primary / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19008588.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


48. Yvgenia R, Ben Meir D, Sibi J, Koren R: Mucinous adenocarcinoma of posterior urethra. Report of a case. Pathol Res Pract; 2005;201(2):137-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of posterior urethra. Report of a case.
  • Primary carcinoma of the male urethra accounts for less than 1% of malignancies in males.
  • Mucinous adenocarcinoma of the urethra is extremely rare, and its biologic behavior is not well known.
  • We report a case of mucinous adenocarcinoma showing the histologic features of colloid adenocarcinoma that appears to have evolved either by neoplastic degeneration of goblet cells found in the urethral epithelium or by malignant degeneration of persistent glandular elements of uretheritis cystica and glandularis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Urethral Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15901135.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Leopoldo S, Lorena B, Cinzia A, Gabriella DC, Angela Luciana B, Renato C, Antonio M, Carlo S, Cristina P, Stefano C, Maurizio T, Luigi R, Cesare B: Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol; 2008 May;15(5):1429-39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features.
  • BACKGROUND: This work is aimed at comparing mucinous colorectal adenocarcinomas (MUC) and non-mucinous colorectal adenocarcinomas (non-MUC), and at verifying the existence of two different subgroups of MUC, in terms of clinicopathological features, chromosomal alterations, and outcome, in a geographical area where mucinous colorectal cancer resulted as being very frequent.
  • RESULTS: MUC accounted for 38.5% of all colorectal carcinomas.
  • CONCLUSION: The results of the present study confirm that MUC represents distinct clinicopathological and genetic features as compared to non-mucinous tumors and support the hypothesis that MUC includes two subtypes with different genetic pathways and behavior.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Microsatellite Instability. Microsatellite Repeats / genetics. Mucin-1 / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Loss of Heterozygosity. Male. Neoplasm Recurrence, Local / diagnosis. Prognosis. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301950.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1
  •  go-up   go-down


50. Abiko K, Baba T, Ogawa M, Mikami Y, Koyama T, Mandai M, Konishi I: Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus. Pathol Int; 2010 Jan;60(1):42-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus.
  • Primary mucinous adenocarcinomas of the uterine corpus are typically low grade and frequently associated with endometrial hyperplasia and/or ordinary endometrioid adenocarcinoma, but may appear as a heterogeneous group of neoplasms.
  • A case is described of a 56-year-old postmenopausal woman who presented with mucinous vaginal discharge.
  • Microscopic examination of hysterectomy specimens indicated highly differentiated mucinous adenocarcinoma diffusely infiltrating the portion of adenomyosis of the corpus.
  • In some areas endometrial glands of adenomyosis were replaced by benign-looking mucinous metaplasia.
  • HIK1083 and MUC6 immunohistochemistry indicated a gastric phenotype of the tumor, as seen in cases of prototypical minimal deviation adenocarcinoma (MDA) of the cervix.
  • In summary, mucinous endometrial adenocarcinoma rarely shows features similar to MDA of the cervix.
  • This case provokes a discussion on diagnostic and management strategy, and histogenesis of mucinous neoplasm of the endometrium.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055951.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


51. Yamaguchi T, Kagawa R, Takahashi H, Takeda R, Sakata S, Nishizaki D: Diagnostic implications of MR imaging for mucinous adenocarcinoma arising from fistula in ano. Tech Coloproctol; 2009 Sep;13(3):251-3
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic implications of MR imaging for mucinous adenocarcinoma arising from fistula in ano.
  • Mucinous adenocarcinoma associated with chronic fistula in ano is rare, and diagnosis is often difficult.
  • Two cases of mucinous adenocarcinoma arising from fistula in ano occur in a patient with longlasting fistulas, persisting for more than 10 years, are presented.
  • This is due to the fact that mucinous adenocarcinomas usually consist of the gathering of many small mucous lakes.
  • This finding has the implications in diagnosing mucinous adenocarcinoma arising from carcinoma in ano.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Cell Transformation, Neoplastic / pathology. Magnetic Resonance Imaging / methods. Rectal Fistula / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Middle Aged. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609741.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


52. Morand C, Verrièle V, Valo I, Remoue P, Paillocher N, Chassevent A: Pure mucinous carcinomas of the breast: prognostic study including DNA flow cytometry. Cytometry B Clin Cytom; 2009 Jan;76(1):56-62
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure mucinous carcinomas of the breast: prognostic study including DNA flow cytometry.
  • BACKGROUND: Prognostic factors for pure mucinous carcinomas of the breast are controversial; data on DNA ploidy and S-phase fraction (SPF) are lacking.
  • METHODS: DNA flow cytometry was performed on 69 fresh or frozen pure mucinous carcinomas samples.
  • These two parameters were of prognostic value respectively for disease-free (P=0.035) and overall survival (0.050).
  • Disease-free and overall survivals were not influenced by nodal status and hormone receptors (HRs) status.
  • Patients with aneuploid tumors had shorter disease-free survival than patients with diploid tumors (P=0.031).
  • CONCLUSION: We identified a subset of patients with a poor prognosis, namely those with large aneuploid tumors.
  • This study confirms the good prognosis of pure mucinous carcinomas, particularly when tumor is less than 2 cm (corresponding to cases without lymph nodes involvement), thus challenging the need for axillary nodal examination.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. DNA / genetics
  • [MeSH-minor] Adult. Aged. Aneuploidy. Disease-Free Survival. Female. Flow Cytometry. Humans. Kaplan-Meier Estimate. Middle Aged. Prognosis. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Clinical Cytometry Society.
  • (PMID = 18642325.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  •  go-up   go-down


53. Alexiou K, Sikalias N, Demonakou M, Mylona SC, Triantafyllis V, Kalogirou A, Antsaklis G: Mucinous adenocarcinoma of the appendix presenting with atypical symptomatology and presence of pseudomyxoma peritonei: a case report. Cases J; 2009;2:9089

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma of the appendix presenting with atypical symptomatology and presence of pseudomyxoma peritonei: a case report.
  • INTRODUCTION: Primary tumors of the appendix are unusual and most of them are carcinoids.
  • CASE PRESENTATION: A female patient with mucous adenocarcinoma of the appendix, which primarily presented as atypical abdominal pain.
  • Diagnosis of the disease was made after appendicectomy and histopathological analysis of the specimen.
  • CONCLUSION: Mucin producing adenocarcinomas of the appendix are a category of rare cancers of the gastrointestinal tract.
  • Although at present they are a well studied pathologic entity, the crucial issue of their preoperative diagnosis remains unsolved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Obstet Gynaecol Res. 2007 Aug;33(4):590-4 [17688638.001]
  • [Cites] Eur J Surg. 1998 Nov;164(11):859-62 [9845132.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • [Cites] Radiographics. 2003 May-Jun;23(3):645-62 [12740466.001]
  • [Cites] Radiology. 2002 Sep;224(3):775-81 [12202713.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):848-52 [7634979.001]
  • (PMID = 20062726.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803886
  •  go-up   go-down


54. Ibáñez J, Erro JM, Aranda F, Almendral ML, Valenti C, Echenique-Elizondo M: [Mucinous adenocarcinoma on chronic perianal fistula treated by neoadjuvant chemoradiotherapy and laparoscopy-assisted abdominoperineal amputation]. Cir Esp; 2006 Mar;79(3):184-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous adenocarcinoma on chronic perianal fistula treated by neoadjuvant chemoradiotherapy and laparoscopy-assisted abdominoperineal amputation].
  • [Transliterated title] Adenocarcinoma mucinoso en fístula perianal de largo tiempo de evolución tratado mediante QT-RT neoadyuvante y amputación abdominoperineal laparoscópica.
  • We present a male patient with a perianal fistula of 30 years' duration that had been treated on several occasions.
  • The patient presented with mucoid anal adenocarcinoma.
  • Mucoid adenocarcinoma on chronic perianal fistula is an infrequent process.
  • Late diagnosis is associated with a poor prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Adenocarcinoma, Mucinous / therapy. Antimetabolites, Antineoplastic / therapeutic use. Anus Neoplasms / complications. Anus Neoplasms / therapy. Fluorouracil / therapeutic use. Laparoscopy. Leucovorin / therapeutic use. Rectal Fistula / complications
  • [MeSH-minor] Chemotherapy, Adjuvant. Chronic Disease. Combined Modality Therapy. Digestive System Surgical Procedures / methods. Humans. Male. Middle Aged. Perineum / surgery. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545286.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


55. Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, Nishimura R: Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol; 2007 May;31(5):664-72
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix.
  • Endocervical-type mucinous adenocarcinoma (ECA) of the uterine cervix is defined as a tumor composed of cells resembling those of the endocervical glands, but recent studies have demonstrated that a minority of ECAs displays a gastric immunophenotype.
  • Fifty-three cases of mucinous adenocarcinoma of the uterine cervix (37 FIGO stage IB, 4 stage IIA, and 12 stage IIB) were reviewed and reevaluated using a newly established morphologic criteria for distinguishing gastric type adenocarcinoma, which was defined as a tumor showing clear and/or pale eosinophilic and voluminous cytoplasm, with distinct cell borders.
  • Following the current World Health Organization scheme (2003), 47 tumors (89%) were classified as ECA, 1 (2%) as intestinal type, 1 (2%) as mixed endocervical and intestinal type, and 4 (8%) as minimal deviation adenocarcinoma.
  • Twelve of 47 (26%) ECAs and all 4 minimal deviation adenocarcinomas, reclassified as gastric type using the novel criteria, were frequently positive for HIK1083 with a rate of 75% (12/16), whereas only 11% (4/37) of nongastric tumors were positive.
  • Patients with gastric-type adenocarcinomas had a significantly decreased 5-year disease-specific survival rate (30 vs. 77%; P<0.0001), and the gastric type morphology was related to a significant risk for disease recurrence compared with the nongastric type (P=0.001; HR, 4.5; 95% confidence interval, 1.42-14.2).
  • HIK1083-positivity was also related to decreased 5-year disease-specific survival rate (38% vs. 74%; P<0.005).
  • Mucinous adenocarcinoma of the uterine cervix with gastric immunophenotype can be a distinct morphologic variant showing an aggressive clinical course.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Gastric Mucosa / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Biomarkers, Tumor / metabolism. Disease-Free Survival. Female. Gastric Mucins / immunology. Gastric Mucins / metabolism. Humans. Immunophenotyping. Japan / epidemiology. Middle Aged. Neoplasm Staging. Retrospective Studies. Staining and Labeling. Survival Rate

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460448.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Gastric Mucins
  •  go-up   go-down


56. Sung CO, Seo JW, Kim KM, Do IG, Kim SW, Park CK: Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma. Mod Pathol; 2008 Dec;21(12):1533-41
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma.
  • Mucin occasionally accumulates intracellularly in colorectal mucinous adenocarcinomas, resulting in signet-ring cell morphology.
  • In the current practice of pathology, there is no definitive rule on how to report a minor component of signet-ring cells in colorectal mucinous adenocarcinomas.
  • We hypothesized that the absence of signet-ring cell component might have a favorable effect on survival of mucinous adenocarcinoma patients.
  • To assess the biological characteristics of colorectal mucinous adenocarcinoma, we analyzed its clinicopathological features, microsatellite instability status, and survival outcomes and compared them with those of colorectal signet-ring cell carcinoma.
  • A total of 266 consecutive colorectal mucinous adenocarcinoma patients and 65 signet-ring cell carcinoma patients were included.
  • Mucinous adenocarcinomas, by comparison with signet-ring cell carcinomas, were characterized by development at an older age, less frequent vascular invasion and lymph node metastasis, and lower TNM stage at presentation.
  • A total of 21 (22%) of 95 mucinous adenocarcinomas and 12 (19%) of 63 signet-ring cell carcinomas were high-frequency microsatellite instability.
  • Patients with mucinous adenocarcinoma had significantly better survival than those with signet-ring cell carcinoma (P<0.0001) or than those with signet-ring cell carcinoma showing >50% extracellular mucin by volume (P<0.0001).
  • In univariate analysis, absence of signet-ring cell component (P=0.0197), absence of vascular invasion, decreased invasion depth, no lymph node metastasis, and lower TNM stage had a favorable effect on survival of mucinous adenocarcinoma patients.
  • Absence of vascular invasion, no lymph node metastasis, and lower TNM stage had a favorable effect on survival of signet-ring cell carcinoma patients.
  • Multivariate analysis showed that higher TNM stage and T stage 4 were independent predictors of poor outcome in patients with mucinous adenocarcinoma.
  • Our observations strongly suggest that pathologists should report the percentage of signet-ring cell component in colorectal mucinous adenocarcinomas and mucinous adenocarcinoma has different biologic behavior compared with signet-ring cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18849918.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Tannous ZS, Avram MM, Zembowicz A, Mihm MC, Liteplo M, Kwan T, Olbricht SM: Treatment of synchronous mucinous carcinoma and endocrine mucin-producing sweat gland carcinoma with Mohs' micrographic surgery. Dermatol Surg; 2005 Mar;31(3):364-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of synchronous mucinous carcinoma and endocrine mucin-producing sweat gland carcinoma with Mohs' micrographic surgery.
  • BACKGROUND: Endocrine mucin-producing sweat gland carcinoma is a very rare cutaneous tumor that has been reported only in three patients previously.
  • We report a case of an endocrine mucin-producing sweat gland carcinoma associated with mucinous carcinoma treated by Mohs' micrographic surgery.
  • OBJECTIVE: The purpose of this report is to test the utility of Mohs' micrographic surgery in the treatment of mucinous carcinomata.
  • METHODS: A 79-year-old female with a 2-year history of four lesions of biopsy-proven endocrine mucin-producing sweat gland carcinomas and mucinous carcinoma was treated with Mohs' micrographic surgery.
  • CONCLUSION: Mohs' micrographic surgery is an appropriate treatment for mucinous carcinomata, including endocrine mucin-producing sweat gland carcinoma and mucinous carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Mohs Surgery. Neoplasms, Multiple Primary / surgery. Orbital Neoplasms / surgery. Sweat Gland Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15841644.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Logan-Collins JM, Lowy AM, Robinson-Smith TM, Kumar S, Sussman JJ, James LE, Ahmad SA: VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol; 2008 Mar;15(3):738-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon.
  • BACKGROUND: High levels of vascular endothelial growth factor (VEGF) in ovarian cancer metastases are associated with a worse prognosis in patients treated with chemotherapy.
  • Patients with mucinous adenocarcinomas metastatic to the peritoneal surfaces can be treated with cytoreductive surgery, and both tumor grade and cytoreduction status are prognostic.
  • We hypothesized that angiogenic indices may be prognostic in patients undergoing cytoreductive surgery for mucinous adenocarcinoma of the appendix and colon.
  • CD 34 counts (blood vessels) and VEGF expression was evaluated by means of immunohistochemistry on specimens from patients undergoing cytoreductive surgery and intraperitoneal hyperthermic perfusion (IPHP) for mucinous adenocarcinoma.
  • RESULTS: A total of 26 males and 9 females, with a mean age of 50 years, underwent cytoreductive surgery and IPHP for mucinous adenocarcinoma of appendiceal (n = 32) or colonic (n = 3) origin.
  • With a mean follow-up of 18 months (range 1-63 months), 23 had disease recurrence and 12 were alive without recurrence.
  • CONCLUSIONS: These results suggest that markers of tumor angiogenesis may predict survival in patients with peritoneal surface metastases from mucinous adenocarcinoma.
  • These findings provoke the hypothesis that antiangiogenic therapies may be effective in patients with this devastating disease.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / therapy. Appendiceal Neoplasms / pathology. Appendiceal Neoplasms / therapy. Biomarkers, Tumor / biosynthesis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / therapy. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043973.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


59. Hama Y, Makita K, Yamana T, Dodanuki K: Mucinous adenocarcinoma arising from fistula in ano: MRI findings. AJR Am J Roentgenol; 2006 Aug;187(2):517-21
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma arising from fistula in ano: MRI findings.
  • OBJECTIVE: The purpose of this study was to describe MRI findings in 11 patients with mucinous adenocarcinomas arising from fistula in ano.
  • Regional areas of lymph node enlargement were considered indirect findings of locally advanced mucinous adenocarcinoma.
  • These MRI findings may help diagnose mucinous adenocarcinomas arising from fistula in ano.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Adenocarcinoma, Mucinous / diagnosis. Anus Neoplasms / complications. Anus Neoplasms / diagnosis. Magnetic Resonance Imaging. Rectal Fistula / complications. Rectal Fistula / diagnosis
  • [MeSH-minor] Adult. Aged. Chronic Disease. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861558.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Marques ML, D'Alessandro GS, Chade DC, Lanzoni VP, Saiovici S, Almeida CJ: Primary mucinous adenocarcinoma of the bladder with signet-ring cells: case report. Sao Paulo Med J; 2007 Sep 6;125(5):297-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous adenocarcinoma of the bladder with signet-ring cells: case report.
  • CONTEXT: Primary adenocarcinomas of the bladder are uncommon and usually occur by contiguity with or hematogenic dissemination of other adenocarcinomas such as colorectal, prostate and gynecological tract carcinomas.
  • Mucinous and signet-ring cell histological patterns are even rarer and it is often difficult to morphologically distinguish them from metastatic colorectal adenocarcinoma.
  • CASE REPORT: We present and discuss a rare case of primary mucinous adenocarcinoma of the bladder with signet-ring cells in a 57-year-old male patient.
  • Other primary sites for the tumor had been excluded and, in the absence of digestive tract tumor and for confirmation that it was a primary bladder tumor, an immunohistochemistry study was performed.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Signet Ring Cell / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Humans. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Mucin-2. Mucins / analysis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094900.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


61. Ito S, Kuwabara N, Kamizuru M, Ikemoto S: [A case of primary mucinous adenocarcinoma of the scrotal contents]. Hinyokika Kiyo; 2009 Jul;55(7):441-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary mucinous adenocarcinoma of the scrotal contents].
  • Left high orchiectomy was performed and the removed tissue was 24 x 16 x 15 cm in size, which had large cystic cavity filled with cloudy and deep-green mucin.
  • Pathological diagnosis was mucinous adenocarcinoma.
  • Systemic X-ray examinations, such as lung, abdominal and pelvic CT scan, upper GI series and barium enema, did not show any abnormal SOL suggesting carcinoma.
  • Therefore, we diagnosed this case as a primary adenocarcinoma in the scrotal contents.
  • [MeSH-major] Adenocarcinoma / pathology. Genital Neoplasms, Male / pathology. Scrotum

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673436.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Winder T, Lenz HJ: Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy. Oncologist; 2010;15(8):836-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy.
  • Peritoneal carcinomatosis has been considered a terminal disease with a median survival time of 5.2-12.6 months.
  • Systemic chemotherapy and cytoreductive surgery (CRS) have long been used to treat macroscopic disease, with limited success.
  • Surgery removes the primary cancer and any dissemination within the peritoneal cavity and adjuvant HIPEC eradicates macroscopic or microscopic tumor residue, thus reducing the risk for recurrence.
  • This approach offers a new potential treatment option for patients with metastatic disease confined to the peritoneum.
  • The present review provides an update of the most recent data on the current therapy for pseudomyxoma peritonei (PMP) and mucinous colorectal adenocarcinoma (MCA) with metastatic disease confined to the peritoneum.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Peritoneal Neoplasms / therapy. Pseudomyxoma Peritonei / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1994 Jan-Feb;51(1):30-4 [8265100.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):109-11 [8129480.001]
  • [Cites] Ann Surg. 1994 Feb;219(2):112-9 [8129481.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1390-408 [7503361.001]
  • [Cites] Br J Cancer. 1995 Dec;72(6):1350-6 [8519644.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Jan;11(1):77-81 [8672747.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1270-6 [16838392.001]
  • [Cites] Ann Surg. 2007 Jan;245(1):104-9 [17197972.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Dis Colon Rectum. 2007 Jan;50(1):37-42 [17115339.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):484-92 [17054002.001]
  • [Cites] Cancer Treat Rev. 2007 Apr;33(2):138-45 [17182192.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1408-14 [17631678.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1429-39 [18301950.001]
  • [Cites] Br J Cancer. 2008 Aug 19;99(4):591-6 [18682713.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2426-32 [18521686.001]
  • [Cites] Ann Surg. 2008 Nov;248(5):829-35 [18948811.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):681-5 [19103728.001]
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):881-7 [19259089.001]
  • [Cites] Annu Rev Pathol. 2009;4:343-64 [19400693.001]
  • [Cites] Cancer J. 2009 May-Jun;15(3):225-35 [19556909.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):63-8 [19917863.001]
  • [Cites] Cancer. 2010 Jan 15;116(2):316-22 [19904805.001]
  • [Cites] Cancer Treat Res. 1996;81:105-19 [8834579.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] Semin Surg Oncol. 1998 Apr-May;14(3):254-61 [9548609.001]
  • [Cites] Rev Esp Enferm Dig. 1998 Aug;90(8):563-72 [9780789.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1176-80 [10496558.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):300-8 [15650641.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):259-64 [15655543.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1305-10 [15857840.001]
  • [Cites] Pathol Int. 2005 Dec;55(12):766-74 [16287491.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):69-76 [16389186.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):551-9 [16699309.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] J Surg Oncol. 2000 Feb;73(2):70-4 [10694641.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] J Surg Oncol. 2000 Oct;75(2):103-7 [11064389.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):164-71 [11266521.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):85-91 [11443613.001]
  • [Cites] J Surg Oncol. 2001 Aug;77(4):282-3 [11473380.001]
  • [Cites] Surg Oncol Clin N Am. 2001 Oct;10(4):915-33, xi [11641098.001]
  • [Cites] Br J Surg. 2002 Dec;89(12):1545-50 [12445064.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):160-7 [12576888.001]
  • [Cites] Gastroenterol Clin Biol. 2003 Apr;27(4):407-12 [12759682.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):508-13 [12794016.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1089-103 [12883241.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):465-72 [12884919.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):178-86 [14761921.001]
  • [Cites] Br J Surg. 2004 Mar;91(3):304-11 [14991630.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):615-21 [15289862.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Br J Surg. 1985 Sep;72(9):715-8 [2994793.001]
  • [Cites] Histopathology. 1987 Mar;11(3):259-72 [2828216.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):364-7 [2910444.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5790-4 [2118420.001]
  • [Cites] Prog Clin Biol Res. 1990;354B:141-70 [2236162.001]
  • [Cites] World J Surg. 1991 Sep-Oct;15(5):562-7 [1949852.001]
  • [Cites] Dis Colon Rectum. 1993 Jan;36(1):49-54 [8380140.001]
  • (PMID = 20656916.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3228029
  •  go-up   go-down


63. Osunkoya AO, Nielsen ME, Epstein JI: Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol; 2008 Mar;32(3):468-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases.
  • Mucinous adenocarcinoma of the prostate is one of the least common variants of prostate cancer.
  • We present 47 cases (1991 to 2006) of mucinous carcinomas treated by radical prostatectomy.
  • Mean patient age at diagnosis was 56 years (range: 44 to 69 y).
  • The mean percentage of tumor composed of the mucinous component was 52% (range: 25% to 90%).
  • Margins were positive in 4 cases of mucinous adenocarcinoma of the prostate.
  • In 12 cases (25.5%), mucinous adenocarcinoma had established extraprostatic extension (EEPE).
  • All together, taking into account both the mucinous and nonmucinous tumor, 20/47 cases (42.5%) had EEPE and 6/47 (12.7%) had positive margins.
  • This study confirms that mucinous adenocarcinoma of the prostate treated by radical prostatectomy is not more aggressive, and possibly even less aggressive than nonmucinous prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / mortality. Prostatectomy. Prostatic Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300802.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


64. Kwatra KS, Prabhakar BR, Jain S: Oestrogen and progesterone receptors in primary mucinous carcinoma of skin. Australas J Dermatol; 2005 Nov;46(4):246-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oestrogen and progesterone receptors in primary mucinous carcinoma of skin.
  • A 74-year-old man presented with a recurrent indolent growth in the left axilla.
  • Fine-needle aspiration cytology and histopathological examination showed a picture of mucinous adenocarcinoma.
  • Clinical examination and systemic investigations failed to detect any primary lesion elsewhere and hence, a diagnosis of primary mucinous carcinoma of the skin was made.
  • This tumour shows histological resemblance to mucinous carcinoma of breast.
  • This observation suggests that there is a potential of using antioestrogenic therapy in patients with primary cutaneous mucinous carcinoma, especially because of its high rate of local recurrence.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197424.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


65. Tabrizi AD, Kalloger SE, Köbel M, Cipollone J, Roskelley CD, Mehl E, Gilks CB: Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol; 2010 Mar;29(2):99-107
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases.
  • Primary ovarian mucinous carcinomas of the intestinal type are uncommon and earlier reports have included cases diagnosed according to older, less stringent, criteria (which would now be considered borderline tumors) and variable numbers of cases of metastatic adenocarcinoma.
  • This study was conducted to identify all cases of primary mucinous carcinoma of the ovary in a population-based registry, diagnosed according to WHO 2003 criteria, and to characterize their histologic features, immunohistochemical expression profile, and outcome.
  • Thirty-one cases of primary ovarian mucinous carcinoma were included in this study.
  • Twenty-six of 31 (83.9%) tumors had expansile stromal invasion, 4 of 31 (12.9%) showed destructive invasion, and 1 of 31 (3.2%) had anaplastic carcinoma in a mural nodule.
  • At follow-up, 6 of 26 patients (23.1%) with tumors showing expansile invasion experienced a recurrence, compared with 1 of 4 patients (25%) with destructive invasion and the single patient (100%) with anaplastic carcinoma.
  • Our findings support current diagnostic criteria for primary ovarian mucinous carcinoma, that is, the presence of expansile invasion, in the absence of destructive invasion, warrants a diagnosis of carcinoma.
  • A large majority of mucinous carcinomas show only an expansile pattern of invasion and are confined to the pelvis at diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173494.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Jung ES, Bae JH, Lee A, Choi YJ, Park JS, Lee KY: Mucinous adenocarcinoma involving the ovary: comparative evaluation of the classification algorithms using tumor size and laterality. J Korean Med Sci; 2010 Feb;25(2):220-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma involving the ovary: comparative evaluation of the classification algorithms using tumor size and laterality.
  • For intraoperative consultation of mucinous adenocarcinoma involving the ovary, it would be useful to have approaching methods in addition to the traditional limited microscopic findings in order to determine the nature of the tumors.
  • Mucinous adenocarcinomas involving the ovaries were evaluated in 91 cases of metastatic mucinous adenocarcinomas and 19 cases of primary mucinous adenocarcinomas using both an original algorithm (unilateral >or=10 cm tumors were considered primary and unilateral <10 cm tumors or bilateral tumors were considered metastatic) and a modified cut-off size algorithm.
  • With 10 cm, 13 cm, and 15 cm size cut-offs, the algorithm correctly classified primary and metastatic tumors in 82.7%, 87.3%, and 89.1% of cases and in 80.6%, 84.9%, and 87.1% of signet ring cell carcinoma (SRC) excluded cases.
  • In total cases and SRC excluded cases, 68.4% and 68.4% of unilateral tumors >or=15 cm were primary, respectively.
  • The diagnostic algorithm using size and laterality, in addition to clinical history, preoperative image findings, and operative findings, is a useful adjunct tool for differentiation of metastatic mucinous adenocarcinomas from primary mucinous adenocarcinomas of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Algorithms. Ovarian Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1447-64 [11075847.001]
  • [Cites] J Korean Med Sci. 2009 Feb;24(1):114-9 [19270823.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):391-400 [12352188.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):985-93 [12826891.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):921-6 [2685680.001]
  • [Cites] Cancer. 1994 Oct 15;74(8):2329-40 [7922984.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):617-35 [10366144.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):152-7 [16300822.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1421-8 [16980943.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):128-38 [18162780.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18(2):209-14 [17624989.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jul;27(3):353-65 [18580313.001]
  • [Cites] Semin Diagn Pathol. 2001 Aug;18(3):161-235 [11554665.001]
  • (PMID = 20119573.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2811287
  • [Keywords] NOTNLM ; Adenocarcinoma, Mucinous / Metastatic / Ovarian Neoplasms / Pimary
  •  go-up   go-down


67. Kazakov DV, Suster S, LeBoit PE, Calonje E, Bisceglia M, Kutzner H, Rütten A, Mentzel T, Schaller J, Zelger B, Baltaci M, Leivo I, Rose C, Fukunaga M, Simpson RH, Yang Y, Carlson JA, Cavazza A, Hes O, Mukensnabl P, Vanecek T, Fidalgo A, Pizinger K, Michal M: Mucinous carcinoma of the skin, primary, and secondary: a clinicopathologic study of 63 cases with emphasis on the morphologic spectrum of primary cutaneous forms: homologies with mucinous lesions in the breast. Am J Surg Pathol; 2005 Jun;29(6):764-82
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of the skin, primary, and secondary: a clinicopathologic study of 63 cases with emphasis on the morphologic spectrum of primary cutaneous forms: homologies with mucinous lesions in the breast.
  • We present the largest series of mucinous carcinoma involving the skin, describing the histopathologic, immunohistochemical, electron microscopic, and cytogenetic findings.
  • In addition, we wished to reevaluate the differential diagnostic criteria for distinguishing primary mucinous carcinomas from histologically similar neoplasms involving the skin secondarily, and study some aspects of their pathogenesis.
  • We demonstrate that primary cutaneous mucinous carcinomas span a morphologic spectrum compatible to their mammary counterparts.
  • Most lesions seem to originate from in situ lesions that may represent, using mammary pathology terminology, ductal hyperplasia, atypical ductal hyperplasia, or ductal carcinoma in situ or a combination of the three.
  • The presence of an in situ component defines the neoplasm as primary cutaneous, but its absence does not exclude the diagnosis; although for such neoplasms, full clinical assessment is essential.
  • Mammary mucinous carcinoma involving the skin: all patients presented with lesions on chest wall, breast, axilla, and these locations can serve as clue to the breast origin.
  • Microscopically, cutaneous lesions were of both pure and mixed type, and this correlated with the primary in the breast.
  • Dirty necrosis was a constant histologic finding in intestine mucinous carcinomas involving the skin, and this feature may serve as a clue to an intestinal origin.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Breast Neoplasms / pathology. Intestinal Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897743.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Lacroix-Triki M, Suarez PH, MacKay A, Lambros MB, Natrajan R, Savage K, Geyer FC, Weigelt B, Ashworth A, Reis-Filho JS: Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol; 2010 Nov;222(3):282-98
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.
  • Mucinous carcinomas are a rare entity accounting for up to 2% of all breast cancers, which have been shown to display a gene expression profile distinct from that of invasive ductal carcinomas of no special type (IDC-NSTs).
  • Here, we have defined the genomic aberrations that are characteristic of this special type of breast cancer and have investigated whether mucinous carcinomas might constitute a genomic entity distinct from IDC-NSTs.
  • Thirty-five pure and 11 mixed mucinous breast carcinomas were assessed by immunohistochemistry using antibodies against oestrogen receptor (ER), progesterone receptor, HER2, Ki67, cyclin D1, cortactin, Bcl-2, p53, E-cadherin, basal markers, neuroendocrine markers, and WT1.
  • Fifteen pure mucinous carcinomas and 30 grade- and ER-matched IDC-NSTs were microdissected and subjected to high-resolution microarray-based comparative genomic hybridization (aCGH).
  • In addition, the distinct components of seven mixed mucinous carcinomas were microdissected separately and subjected to aCGH.
  • Pure mucinous carcinomas consistently expressed ER (100%), lacked HER2 expression (97.1%), and showed a relatively low level of genetic instability.
  • Unsupervised hierarchical cluster analysis revealed that pure mucinous carcinomas were homogeneous and preferentially clustered together, separately from IDC-NSTs.
  • They less frequently harboured gains of 1q and 16p and losses of 16q and 22q than grade- and ER-matched IDC-NSTs, and no pure mucinous carcinoma displayed concurrent 1q gain and 16q loss, a hallmark genetic feature of low-grade IDC-NSTs.
  • Finally, both components of all but one mixed mucinous carcinoma displayed similar patterns of genetic aberrations and preferentially clustered together with pure mucinous carcinomas on unsupervised clustering analysis.
  • Our results demonstrate that mucinous carcinomas are more homogeneous between themselves at the genetic level than IDC-NSTs.
  • Both components of mixed mucinous tumours are remarkably similar at the molecular level to pure mucinous cancers, suggesting that mixed mucinous carcinomas may be best classified as variants of mucinous cancers rather than of IDC-NSTs.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Breast Neoplasms / genetics. Carcinoma, Ductal, Breast / genetics


69. Kuroda N, Fujishima N, Ohara M, Hirouchi T, Mizuno K, Lee GH: Invasive ductal carcinoma of the breast with signet-ring cell and mucinous carcinoma components: diagnostic utility of immunocytochemistry of signet-ring cells in aspiration cytology materials. Diagn Cytopathol; 2007 Mar;35(3):171-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive ductal carcinoma of the breast with signet-ring cell and mucinous carcinoma components: diagnostic utility of immunocytochemistry of signet-ring cells in aspiration cytology materials.
  • In this article, we present a case of invasive ductal carcinoma with signet-ring cells and mucinous carcinoma components, which could be diagnosed as a primary cancer by immunocytochemical study of fine-needle aspiration cytology material.
  • The histological examination of surgically resected breast tumor showed invasive ductal carcinoma with foci of signet-ring cell and mucinous carcinomas.
  • Finally, our preliminary report suggests that immunocytochemical examination of aspiration cytology materials may provide useful information in searching the primary site of breast carcinoma with signet-ring cells.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Signet Ring Cell / diagnosis

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415922.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM: Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol; 2006 Jan;19(1):97-105
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases.
  • Estrogen (ER) and progesterone receptor (PR) expression in primary ovarian mucinous tumors and the utility of these markers for distinguishing metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors have not been extensively investigated.
  • Immunohistochemical studies were performed on 124 mucinous tumors, including 52 primary ovarian tumors (30 atypical proliferative (borderline) mucinous tumors of gastrointestinal type, 11 atypical proliferative (borderline) mucinous tumors of seromucinous (endocervical-like) type, and 11 invasive mucinous carcinomas of usual (gastrointestinal) type) and 72 metastatic mucinous carcinomas in the ovary (primary sites: colorectum (24), pancreas (13), endocervix (eight), stomach (four), gallbladder/bile duct (four), appendix (four), and unknown (15)).
  • All atypical proliferative mucinous tumors of gastrointestinal type, primary ovarian mucinous carcinomas, and metastatic mucinous carcinomas were negative for ER and PR with the exception of three metastatic endocervical adenocarcinomas which exhibited only weak expression of ER without PR.
  • All atypical proliferative mucinous tumors of seromucinous type expressed ER to some degree and seven had some expression of PR.
  • Immunohistochemical assessment of hormone receptor expression is of no value in distinguishing the common types of primary ovarian mucinous tumors (atypical proliferative mucinous tumors of gastrointestinal type and mucinous carcinomas of usual type) from the vast majority of mucinous carcinomas metastatic to the ovary.
  • The above observations on hormone receptor expression in primary ovarian mucinous tumors support the concept that atypical proliferative (borderline) mucinous tumors of gastrointestinal and seromucinous (endocervical-like) types are distinctive tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Ovarian Neoplasms / secondary. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis
  • [MeSH-minor] Appendiceal Neoplasms / metabolism. Appendiceal Neoplasms / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Diagnosis, Differential. Female. Gallbladder Neoplasms / metabolism. Gallbladder Neoplasms / pathology. Humans. Immunohistochemistry. Neoplasms, Unknown Primary / metabolism. Neoplasms, Unknown Primary / pathology. Ovary / chemistry. Ovary / pathology. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294196.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


71. Kountourakis P, Ardavanis A, Mantzaris I, Mitsaka D, Rigatos G: Urachal mucinous adenocarcinoma: a case report. J BUON; 2007 Oct-Dec;12(4):547-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urachal mucinous adenocarcinoma: a case report.
  • Adenocarcinomas account for 0.5-2% of all bladder cancers.
  • Urachal carcinoma is a rare neoplasm which represents 0.01% of all cancers in adults and account for one third of bladder adenocarcinomas.
  • A 65-year-old white man with an urachal mucinous adenocarcinoma is reported.
  • He underwent a partial cystectomy and en block excision of the umbilical ligament and remains disease-free after one year.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Urachus. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Urachal adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067216.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


72. Soto Delgado M, Pedrero Márquez G, Varo Solís C, Rodríguez-Rubio Cortadellas FO, Sánchez Bernal C, González Moreno D: [Mucinous adenocarcinoma of the urachus and peritoneal pseudomyxoma]. Actas Urol Esp; 2006 Feb;30(2):222-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous adenocarcinoma of the urachus and peritoneal pseudomyxoma].
  • [Transliterated title] Adenocarcinoma mucinoso de uraco y pseudomixoma peritoneal.
  • The adenocarcinoma of the urachus is very rare tumor, with an incidence of 1/5.000.000 inhabitants, represents less than 0.001 of all types of bladder cancer.
  • Peritoneal pseudomixoma is a rare neoplasm characterized by mucinous acites that involvement the peritoneal surface and omentum.
  • Usually is associated with benign o malignant mucinous tumor of the appendix or ovary.
  • In this paper, we present a case of peritoneal pseudomixoma caused by a mucinous adenocarcinoma of the urachus.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Pseudomyxoma Peritonei / etiology. Urachus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700214.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


73. Kim JC, Cho YK, Roh SA, Yu CS, Gong G, Jang SJ, Kim SY, Kim YS: Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors. Cancer Sci; 2008 Jul;99(7):1348-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors.
  • Clinicopathologic features of sporadic colorectal adenocarcinomas were compared using integrated data from 224 [corrected] patients subjected to curative resection.
  • Poorly differentiated or mucinous adenocarcinomas were generally associated with high level microsatellite instability, Axin2 suppression, TGF-beta1 or BMPR1A suppression, loss of heterozygosity of D18S46 or D18S474, and absence of base excision repair mutations (P < 0.0001-0.05).
  • [MeSH-major] Adenocarcinoma / etiology. Colorectal Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Sci. 2008 Jul;99(7):1499
  • (PMID = 18422752.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.1 / raf Kinases
  •  go-up   go-down


74. Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, Pise-Masison C, Brady J, Hao K, Berkowitz RS, Mok S, Birrer MJ: Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res; 2006 Feb 1;12(3 Pt 1):690-700
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
  • PURPOSE: To elucidate the molecular mechanisms contributing to the unique clinicopathologic characteristics of mucinous ovarian carcinoma, global gene expression profiling of mucinous ovarian tumors was carried out.
  • EXPERIMENTAL DESIGN: Gene expression profiling was completed for 25 microdissected mucinous tumors [6 cystadenomas, 10 low malignant potential (LMP) tumors, and 9 adenocarcinomas] using Affymetrix U133 Plus 2.0 oligonucleotide microarrays.
  • Hierarchical clustering and binary tree prediction analysis were used to determine the relationships among mucinous specimens and a series of previously profiled microdissected serous tumors and normal ovarian surface epithelium.
  • PathwayAssist software was used to identify putative signaling pathways involved in the development of mucinous LMP tumors and adenocarcinomas.
  • RESULTS: Comparison of the gene profiles between mucinous tumors and normal ovarian epithelial cells identified 1,599, 2,916, and 1,765 differentially expressed in genes in the cystadenomas, LMP tumors, and adenocarcinomas, respectively.
  • Hierarchical clustering showed that mucinous and serous LMP tumors are distinct.
  • In addition, there was a close association of mucinous LMP tumors and adenocarcinomas with serous adenocarcinomas.
  • Binary tree prediction revealed increased heterogeneity among mucinous tumors compared with their serous counterparts.
  • Furthermore, the cystadenomas coexpressed a subset of genes that were differentially regulated in LMP and adenocarcinoma specimens compared with normal ovarian surface epithelium.
  • PathwayAssist highlighted pathways with expression of genes involved in drug resistance in both LMP and adenocarcinoma samples.
  • In addition, genes involved in cytoskeletal regulation were specifically up-regulated in the mucinous adenocarcinomas.
  • CONCLUSIONS: These data provide a useful basis for understanding the molecular events leading to the development and progression of mucinous ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cluster Analysis. Decision Trees. Diagnosis, Differential. Female. Humans. Oligonucleotide Array Sequence Analysis / methods. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467078.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


75. Yoon MA, Lee JM, Kim SH, Lee JY, Han JK, Choi BI, Choi JY, Park SH, Lee MW: MRI features of pancreatic colloid carcinoma. AJR Am J Roentgenol; 2009 Oct;193(4):W308-13
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI features of pancreatic colloid carcinoma.
  • OBJECTIVE: The purpose of our study was to retrospectively investigate the MRI findings (diameter, location, contour and margin, signal intensity characteristics, and enhancement patterns) in a series of eight patients with pathologically proven colloid carcinoma of the pancreas.
  • CONCLUSION: Colloid carcinomas of the pancreas appear as masses with lobulating contours, indiscrete margins, and hyperintensity on T2-weighted images (n = 8).
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19770300.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. McKenney JK, Soslow RA, Longacre TA: Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol; 2008 May;32(5):645-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
  • Mucinous epithelial neoplasms arising in association with mature teratomas are a heterogeneous group of tumors, but with the exception of a single recent study, their full histologic spectrum, detailed immunophenotype, and association with classic pseudomyxoma peritonei (PMP) have not been fully studied.
  • The morphologic, immunohistochemical, and clinical features of 42 patients with mucinous epithelial tumors arising in association with mature ovarian teratomas were evaluated.
  • Most teratoma-associated mucinous tumors were unilateral, although 1 patient harbored bilateral mucinous tumors in association with bilateral teratomas.
  • Using the 2003 World Health Organization criteria for ovarian intestinal type mucinous neoplasms, 17 (40%) were classified as mucinous cystadenoma, 16 (38%) as intestinal-type mucinous epithelial neoplasm of low malignant potential (IM-LMP), 4 (10%) as intraepithelial carcinoma (IEC), and 5 (12%) as invasive mucinous carcinoma.
  • Mucinous cystadenomas had a varied epithelial lining consisting of lower gastroenteric, gastric foveolar, or müllerian appearance.
  • In contrast, the IM-LMP, IEC, and invasive carcinoma cases had a more uniform lower gastroenteric histology.
  • For mucinous cystadenomas, a cytokeratin (CK) 7+/CK20- phenotype (5/13; 38%) was equally as common as a CK7-/CK20+ phenotype (5/13; 38%), with the remaining cases coexpressing both keratins (CK7+/CK20+: 3/13; 23%).
  • In contrast, IM-LMP, IEC, and invasive adenocarcinomas more frequently had a CK7-/CK20+ phenotype (56%, 50%, and 100%, respectively).
  • A CK7+/CK20-phenotype was rare in these later 3 morphologic groups (6%).
  • Of the 42 total cases, 55% had pseudomyxoma ovarii and 24% had classic PMP (1 cystadenoma, 6 IM-LMP, and 3 invasive carcinomas), whereas 5% had more localized accumulations of peritoneal mucin (both IM-LMP).
  • Pathologic evaluation of the peritoneum in these 12 cases revealed 6 with acellular mucin alone, 3 with low-grade mucinous epithelium (all 3 with ovarian IM-LMP), and 3 with high-grade mucinous carcinomatosis (all 3 with ovarian mucinous adenocarcinoma).
  • The only adverse outcomes occurred in the 3 patients with ovarian carcinoma and associated peritoneal carcinomatosis.
  • We report that a significant proportion of mucinous tumors associated with mature ovarian teratomas present with clinical PMP, which in most cases is associated with IM-LMP.
  • PMP in this setting may harbor microscopic intra-abdominal low-grade mucinous epithelium that is histologically and immunophenotypically similar to that typically seen in appendiceal-related PMP.
  • Pseudomyxoma ovarii is common in this setting, particularly in tumors with IM-LMP histology, but pseudomyxoma ovarii is not predictive of PMP.
  • Ovarian teratoma-associated benign and IM-LMP mucinous neoplasms with microscopic peritoneal low-grade mucinous epithelium do not seem to be at significant risk for intra-abdominal recurrence, but numbers are few and follow-up is limited.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Mucins / metabolism. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344868.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


77. Freeman HJ, Perry T, Webber DL, Chang SD, Loh MY: Mucinous carcinoma in Crohn's disease originating in a fistulous tract. World J Gastrointest Oncol; 2010 Jul 15;2(7):307-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma in Crohn's disease originating in a fistulous tract.
  • Malignant disease, including mucinous carcinomas of the colorectum, may complicate long-standing Crohn's disease.
  • An 18-year-old male with extensive small and large bowel involvement with Crohn's disease developed recurrent peri-rectal fistulous disease that persisted for more than a decade despite pharmacological and surgical therapy as well as later therapy with biological agents.
  • Eventually, an extensive and difficult-to-detect mucinous carcinoma developed in the fistulous tract.
  • Although fistula cancer is rarely described in Crohn's disease, use of immunosuppressant and biological agents may play an initiating or exacerbating role in its development or progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160662.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999135
  • [Keywords] NOTNLM ; Adalimumab / Anal fistula / Anorectal adenocarcinoma / Crohn’s disease / Fistula carcinoma / Infliximab / Tumor necrosis factor antibodies
  •  go-up   go-down


78. Hanagiri T, Ono K, Baba T, So T, Yamasaki M, Nagata Y, Uramoto H, Takenoyama M, Yasumoto K: Clinicopathologic characteristics of mucinous carcinoma of the breast. Int Surg; 2010 Apr-Jun;95(2):126-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics of mucinous carcinoma of the breast.
  • The mucinous carcinoma of breast cancer is a relatively rare malignant tumor.
  • This study investigated the clinical and pathologic features of mucinous carcinoma.
  • These cases included 10 patients (4.2%) with mucinous carcinoma.
  • The 10-year survival rates of mucinous carcinoma and other types of invasive breast cancer were 87.5% and 80.7%, respectively.
  • Mucinous carcinoma showed a lower incidence of lymph node metastasis than other types of invasive breast cancer.
  • Mucinous carcinoma tended to have a better prognosis in comparison with other types of invasive breast carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Breast Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20718318.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


79. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT: Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol; 2010 Aug;116(2 Pt 1):269-73
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary.
  • OBJECTIVE: To estimate the prevalence of lymph node involvement in women with primary mucinous ovarian carcinomas.
  • METHODS: A retrospective study was performed of patients with primary mucinous ovarian carcinomas evaluated at a single institution between 1985 and 2007.
  • Patients with tumors of low malignant potential and mucinous carcinomas metastatic to the ovary from other primary sites were excluded.
  • RESULTS: Patients with primary mucinous ovarian carcinomas were identified (n=107).
  • All patients underwent primary surgery.
  • At time of surgery, 93 patients (87%) had tumors that grossly appeared to be confined to the ovary, and 14 patients (13%) had evidence of extraovarian disease.
  • Of these 51 patients, none had metastatic disease to the pelvic or paraaortic lymph nodes.
  • CONCLUSION: There were no cases of isolated lymph node metastases among women with primary mucinous carcinoma grossly confined to the ovary, suggesting that routine lymphadenectomy may be omitted in these patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Lymph Nodes / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2001 Jan 20;357(9251):176-82 [11213094.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):198-205 [12892797.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):918-33 [15297960.001]
  • [Cites] Gynecol Oncol. 2009 Jun;113(3):331-4 [19275957.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):436-41 [15863142.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):878-82 [16859736.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):624-9 [15350350.001]
  • (PMID = 20664385.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS625325; NLM/ PMC4163054
  •  go-up   go-down


80. Kim KR, Lee HI, Lee SK, Ro JY, Robboy SJ: Is stromal microinvasion in primary mucinous ovarian tumors with "mucin granuloma" true invasion? Am J Surg Pathol; 2007 Apr;31(4):546-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is stromal microinvasion in primary mucinous ovarian tumors with "mucin granuloma" true invasion?
  • Stromal microinvasion has been recently described in ovarian mucinous borderline tumors (MBTs), leading to proposals for new classifications, including a category of MBTs with stromal microinvasion.
  • To determine whether stromal microinvasion can be distinguishable from extruded neoplastic epithelium from an adjacent ruptured gland, particularly if accompanied by a mucin granuloma (MG) on hematoxylin and eosin (H&E)-stained sections, we compared the histopathologic features of 138 primary ovarian mucinous tumors, consisting of 81 MBTs, 37 MBTs with stromal microinvasion, 11 intraglandular carcinomas, 2 with microinvasive foci, and 7 mucinous adenocarcinomas with extensive stromal invasion.
  • All patients with MBT with or without microinvasive foci and localized intraglandular carcinoma with or without microinvasive foci had stage I tumors; none died of tumor-related causes during the follow-up period.
  • This study suggests that some cases of stromal microinvasion in stage I MBTs not accompanied by high grade nuclear atypia represent mucocele-like stromal reaction to ruptured mucinous glands rather than true stromal invasion because isolated tumor cells were exclusively confined to the boundary of MGs and devoid of obvious cellular atypia, and no patient with stromal microinvasion died of tumor-related causes.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Neoplasm Metastasis / pathology. Ovarian Neoplasms / classification. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414101.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Kondo T, Hashi A, Murata S, Nakazawa T, Yuminamochi T, Nara M, Hoshi K, Katoh R: Endocervical adenocarcinomas associated with lobular endocervical glandular hyperplasia: a report of four cases with histochemical and immunohistochemical analyses. Mod Pathol; 2005 Sep;18(9):1199-210
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinomas associated with lobular endocervical glandular hyperplasia: a report of four cases with histochemical and immunohistochemical analyses.
  • We report on four cases of endocervical adenocarcinoma associated with lobular endocervical glandular hyperplasia using histochemical and immunohistochemical analyses.
  • Cytological examinations of the cervical smears revealed adenocarcinoma cells and benign-looking glandular cells with intracytoplasmic golden-yellow mucin in all cases.
  • From surgical specimens, three tumors were diagnosed as mucinous adenocarcinoma and one was adenocarcinoma in situ.
  • All adenocarcinomas were located proximally on the cervix, and did not involve the transformation zone.
  • Adjacent to carcinoma tissues in the cervix, lobular endocervical glandular hyperplasia was detected.
  • The cells of lobular endocervical glandular hyperplasia were dominantly positive with neutral mucin, and immunohistochemistry revealed that these cells had prominent pyloric gland mucin (HIK1083).
  • Focal immunopositivity for pyloric mucin was also observed in three adenocarcinomas.
  • Either CEA or p53 were immunopositive in all adenocarcinomas and negative in the tissues of lobular endocervical glandular hyperplasia.
  • Histopathological features of the present cases suggest that some endocervical adenocarcinomas may originate from lobular endocervical glandular hyperplasia.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / pathology. Hyperplasia / complications. Hyperplasia / pathology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Middle Aged. Mucins / metabolism. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761489.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


82. Osunkoya AO, Adsay NV, Cohen C, Epstein JI, Smith SL: MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy. Mod Pathol; 2008 Jul;21(7):789-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy.
  • The expression of mucin (MUC2) in prostate cancer has not been well studied previously and may be of prognostic and pathobiologic significance.
  • It is, however, well known that MUC2 expression in mucinous pancreatic and breast cancer represents an indolent pathway since these tumors have a significantly better outcome than their conventional counterparts.
  • Twenty-five cases each of Gleason pattern 3 and 4 mucinous adenocarcinoma of the prostate defined by greater than 25% mucinous component and nonmucinous adenocarcinoma of the prostate were obtained from the surgical pathology files of the Johns Hopkins Hospital and Emory University Hospital.
  • MUC2 was expressed in all 25 cases (100%) of mucinous adenocarcinoma of the prostate, irrespective of the Gleason pattern.
  • In contrast, MUC2 expression was significantly lower in nonmucinous adenocarcinoma of the prostate, detected in only 6/25 cases as a focal finding, while 19/25 (76%) of nonmucinous adenocarcinoma of the prostate were completely negative for MUC2 (P<0.01).
  • In six cases that showed focal positivity, MUC2 was expressed in areas with Gleason pattern 3 cancer with extensive mucinous fibroplasia (one case) and prominent intraluminal mucin (five cases).
  • Mucinous adenocarcinoma of the prostate shows diffuse expression of MUC2, a known tumor suppressor, which is not present in either normal prostate or the majority of conventional adenocarcinomas of this organ.
  • This indicates that mucinous adenocarcinoma of the prostate is indeed of the 'colloid type' akin to those in other exocrine organs.
  • It is highly conceivable that this de novo expression of MUC2 has a role, not only in the mucinous differentiation of these tumors and their colloid pattern, but also in their relatively indolent behavior that has been recently elucidated.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Biomarkers, Tumor / metabolism. Mucins / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Humans. Immunoenzyme Techniques. Male. Middle Aged. Mucin-2. Prostate / anatomy & histology. Prostate / metabolism. Prostatectomy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487999.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


83. Lin X, Lindner JL, Silverman JF, Liu Y: Intestinal type and endocervical-like ovarian mucinous neoplasms are immunophenotypically distinct entities. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):453-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal type and endocervical-like ovarian mucinous neoplasms are immunophenotypically distinct entities.
  • Ovarian mucinous neoplasm (OMN) is traditionally classified as either intestinal type or endocervical-like subtypes.
  • In this study, we investigated 14 intestinal type OMNs (borderline and adenocarcinoma) and 12 endocervical-like OMNs (borderline and adenocarcinoma) for their expression of PDX-1, CDX-2, CA-125, CK7, CK20, WT-1, D2-40, and TTF-1.
  • We also included 15 colorectal adenocarcinomas metastatic in the ovary, as they may occasionally mimic OMN.
  • Metastatic colorectal adenocarcinomas were positive for CK20 (100%), CDX-2 (100%), and PDX-1 (33%), whereas were negative for CA-125 and CK7.
  • All of the intestinal type and endocervical-like OMNs as well as metastatic colorectal adenocarcinomas were negative for WT-1, D2-40, and TTF-1.
  • The 2 subtypes can be separated from metastatic colorectal adenocarcinoma by the different immunohistochemical profile of PDX-1, CA-125, CK7, CK20, and CDX-2.
  • In the work-up of mucinous adenocarcinoma in the ovary or abdominal cavity, caution should be exercised in interpreting the possible primary site on the basis of the immunohistochemical profiles.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665037.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Transcription Factors
  •  go-up   go-down


84. Kanoh A, Seko A, Ideo H, Yoshida M, Nomoto M, Yonezawa S, Sakamoto M, Kannagi R, Yamashita K: Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas. Glycoconj J; 2006 Jul;23(5-6):453-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas.
  • Mucinous and clear cell adenocarcinomas are the major histological types of ovarian epithelial cancer and are associated with a poor prognosis due to their resistance to chemotherapy.
  • A novel tumor marker specific for ovarian mucinous and clear cell adenocarcinomas would be helpful for overcoming these serious diseases.
  • We showed previously by enzymological characterization and RT-PCR that colonic mucinous adenocarcinoma tissues ectopically express GlcNAc6ST-2, a member of the carbohydrate 6-O-sulfotransferase family (Seko, A. et al. (2002) Glycobiology 12, 379-388).
  • Here, we prepared a GlcNAc6ST-2-specific polyclonal antibody for immunohistochemical analysis and found that GlcNAc6ST-2 is ectopically expressed by not only colonic mucinous adenocarcinomas but also ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • In contrast, solid serous adenocarcinomas, endometrioid adenocarcinomas, and mucinous adenomas expressed GlcNAc6ST-2 much less frequently or not at all.
  • RT-PCR analysis confirmed that GlcNAc6ST-2 transcripts are expressed in ovarian mucinous adenocarcinomas but not in mucinous adenomas.
  • In addition, immunohistochemical analysis using sulfated glycan-specific monoclonal antibodies showed that ovarian adenocarcinoma cells express GlcNAc 6-O-sulfated glycans, including an L-selectin ligand and its related glycans.
  • These results indicate that GlcNAc6ST-2 would be a novel tumor antigen that is specifically expressed in ovarian mucinous, clear cell and papillary serous adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / enzymology. Drug Resistance, Neoplasm / physiology. Ovarian Neoplasms / enzymology. Sulfotransferases / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16897186.001).
  • [ISSN] 0282-0080
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.- / carbohydrate sulfotransferases
  •  go-up   go-down


85. Okamoto Y, Tanaka YO, Tsunoda H, Yoshikawa H, Minami M: Malignant or borderline mucinous cystic neoplasms have a larger number of loculi than mucinous cystadenoma: a retrospective study with MR. J Magn Reson Imaging; 2007 Jul;26(1):94-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant or borderline mucinous cystic neoplasms have a larger number of loculi than mucinous cystadenoma: a retrospective study with MR.
  • PURPOSE: To determine whether there is any correlation between the number of loculi and the pathological grade of malignancy in mucinous cystic tumors of the ovary.
  • MATERIALS AND METHODS: We retrospectively studied MR images of 67 pathologically proven mucinous cystic tumors of the ovaries.
  • Of these 67 cases, 38 were cystadenomas and 29 were malignant lesions (18 borderline malignancy and 11 adenocarcinomas).
  • RESULTS: The mean number of loculi was 18.2 in cystadenoma and 80.9 in malignant lesions.
  • The mean maximum diameter of tumors was 13.0 cm in cystadenoma and 18.7 cm in malignant lesions.
  • The mean ratio of the number of loculi to the maximum diameter was 1.3 in adenoma and 5.4 in malignant lesions.
  • The differences between the benign and malignant lesions were statistically significant in number (P = 0.001), maximum diameter (P = 0.011), and ratio (P = 0.002).
  • CONCLUSION: Ovarian mucinous neoplasm of borderline malignancy and mucinous adenocarcinomas had a larger number of loculi than adenomas.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Magnetic Resonance Imaging / methods. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17659568.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


86. Xambre L, Cerqueira M, Cardoso A, Correia T, Macedo Dias A, Carreira F, Galán T: [Primary mucinous adenocarcinoma of the renal pelvis--adicional case report]. Actas Urol Esp; 2009 Feb;33(2):200-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mucinous adenocarcinoma of the renal pelvis--adicional case report].
  • [Transliterated title] Adenocarcinoma mucinoso primário de pélvis renal--caso adicional.
  • Mucinous adenocarcinoma of the renal pelvis may be classified as among the rarest neoplasms of the genitourinary tract.
  • Despite the known association with chronic inflammatory conditions of the upper urinary tract, the exact pathogenesis remains unknown.
  • The authors report an adicional clinical case with particular aspects in what concerns differential diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous. Kidney Neoplasms. Kidney Pelvis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19418847.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 13
  •  go-up   go-down


87. Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Judson K, Ronnett BM: p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol; 2007 May;31(5):653-63
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
  • Distinction of primary ovarian epithelial tumors from metastatic adenocarcinomas is challenging for tumors exhibiting mucinous, endometrioid, or mixed endometrioid/mucinous differentiation.
  • Metastatic carcinomas with these types of differentiation can be derived from several sites, including the gastrointestinal tract and the uterus.
  • Most endocervical adenocarcinomas exhibit mucinous and/or endometrioid differentiation; they infrequently metastasize to the ovaries but may simulate primary ovarian tumors [both atypical proliferative (borderline) and carcinoma].
  • The performance of this expression pattern for identifying metastatic endocervical adenocarcinomas in the ovaries among primary ovarian tumors and other metastatic adenocarcinomas having mucinous and/or endometrioid/endometrioidlike differentiation has not been evaluated.
  • Immunohistochemical expression of p16 was assessed in 195 tumors, including 98 primary ovarian tumors (51 mucinous, 47 endometrioid, and 4 mixed mucinous-endometrioid tumors), 93 metastatic adenocarcinomas of known primary sites (colorectum: 34, endocervix: 19, pancreaticobiliary tract: 17, appendix: 7, stomach: 5), 11 metastatic adenocarcinomas of unknown origin (7 established as noncervical), and 4 adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin.
  • The HPV status of the endocervical adenocarcinomas was determined by in situ hybridization and polymerase chain reaction (when in situ hybridization was negative).
  • Mean and median expression values for HPV-positive endocervical adenocarcinomas (99%, 100%; range 90% to 100%) were substantially higher than those for primary ovarian mucinous (5%, 0%; range 0% to 70%) and endometrioid (20%, 10%; range 0% to 100%) tumors, HPV-unrelated endocervical adenocarcinomas (0%, 0%; range 0% to 60%), metastatic adenocarcinomas of unknown origin (11%, 0%; range 0% to 30%), and adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin (40%, 35%; range 0% to 90%); only the 15 HPV-positive endocervical adenocarcinomas and 6 other tumors had values of 80% or greater.
  • Diffuse (>75% positive tumor cells) moderate to strong p16 expression is a sensitive (100%) and specific (97%) marker for identifying HPV-related endocervical adenocarcinomas metastatic to the ovary among the primary ovarian tumors and metastatic adenocarcinomas from other sites that are in the differential diagnosis of ovarian tumors having mucinous and/or endometrioid/endometrioidlike differentiation. p16 is useful as part of a panel of immunohistochemical markers for distinguishing primary ovarian tumors from metastases and, when diffusely positive, can suggest the cervix as a potential primary site for metastatic adenocarcinomas of unknown origin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Endometrioid / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Ovarian Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. DNA, Viral / analysis. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomaviridae / genetics. Papillomavirus Infections. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460447.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral
  •  go-up   go-down


88. Yoon SO, Kim BH, Lee HS, Kang GH, Kim WH, Kim YA, Kim JE, Chang MS: Differential protein immunoexpression profiles in appendiceal mucinous neoplasms: a special reference to classification and predictive factors. Mod Pathol; 2009 Aug;22(8):1102-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential protein immunoexpression profiles in appendiceal mucinous neoplasms: a special reference to classification and predictive factors.
  • Appendiceal mucinous neoplasms have been the focus of considerable debate in recent years.
  • We histologically classified 70 appendiceal mucinous neoplasms into three categories: 32 mucinous adenoma, 23 mucinous neoplasm of uncertain malignant potential, and 15 mucinous adenocarcinomas.
  • Immunohistochemistry was performed for 24 proteins in different functional categories, specifically, oncogenic proteins (bcl-2, beta-catenin, CEA, C-erbB2, c-kit, Cox-2, Cyclin D1, EGFR, Ki-67, NF-kappaB, VEGF), tumor suppressors (E-cadherin, FHIT, hMLH1, p53, p63, smad4), cell-cycle regulators (p21, p27, p16), and mucin proteins (MUC1, MUC2, MUC5AC, MUC6).
  • Our data showed that 9 out of the 24 proteins were more frequently altered in the mucinous adenocarcinoma group than in the mucinous adenoma group (P<0.05), including beta-catenin (13% in mucinous adenoma vs 60% in mucinous adenocarcinoma), CyclinD1 (44 vs 87%), Ki-67 (high labeling index: 31 vs 67%), NF-kappaB (19 vs 60%), VEGF (16 vs 87%), E-cadherin (0 vs 47%), p53 (6 vs 40%), MUC2 (9 vs 67%), and MUC5AC (3 vs 40%).
  • The distinct immunoexpression profile of mucinous neoplasm of uncertain malignant potential was placed between those of mucinous adenoma and mucinous adenocarcinoma (P<0.05).
  • Moreover, the mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma categories displayed differences in terms of the number of altered markers among the nine proteins (P<0.05; mean 1.4 vs 2.6 vs 5.5, respectively).
  • In mucinous adenocarcinoma, the p53 status was related to disease-free survival and overall survival of patients (P<0.05, both).
  • NF-kappaB status and the number of altered protein markers made statistically marginal impacts on disease-free survival; also beta-catenin loss, on overall survival of patients.
  • In conclusion, protein immunoexpression profiles may facilitate the classification of appendiceal mucinous neoplasms.
  • In our study, the three tumor categories of mucinous adenoma, mucinous neoplasm of uncertain malignant potential, and mucinous adenocarcinoma exhibited distinct immunoexpression profiles.
  • Five and more altered protein markers, p53 overexpression, NF-kappaB positivity, and beta-catenin loss were predictive factors of adverse clinical outcomes in appendiceal mucinous adenocarcinomas.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Appendiceal Neoplasms / pathology. Biomarkers, Tumor / analysis. Cystadenoma, Mucinous / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease-Free Survival. Female. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. NF-kappa B / biosynthesis. NF-kappa B / genetics. Prognosis. Tissue Array Analysis. Tumor Suppressor Protein p53 / biosynthesis. Tumor Suppressor Protein p53 / genetics. Young Adult. beta Catenin / biosynthesis. beta Catenin / genetics


89. Larrousse C, Brasseur P, Sukkarieh F: [Port-site metastasis following laparoscopic radical prostatectomy for mucinous adenocarcinoma of the prostate]. J Radiol; 2005 Mar;86(3):337-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Port-site metastasis following laparoscopic radical prostatectomy for mucinous adenocarcinoma of the prostate].
  • [Transliterated title] Métastase orificielle après prostatectomie radicale coelioscopique pour un adénocarcinome mucineux de la prostate.
  • A 52-year-old man underwent laparoscopic radical prostatectomy for mucinous adenocarcinoma.
  • Eight months later, an abdominal wall metastasis developed at the trocar site through which the laparoscope had been introduced.
  • To our knowledge, it is the first reported case of port site metastasis after laparoscopic radical prostatectomy.
  • [MeSH-major] Abdominal Neoplasms / secondary. Abdominal Wall. Adenocarcinoma, Mucinous / secondary. Laparoscopy / adverse effects. Neoplasm Seeding. Prostatectomy / methods. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908875.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


90. Zen Y, Sasaki M, Fujii T, Chen TC, Chen MF, Yeh TS, Jan YY, Huang SF, Nimura Y, Nakanuma Y: Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol; 2006 Feb;44(2):350-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis.
  • RESULTS: Thirty-seven cases of ICC in hepatolithiasis were divided into 18 tubular adenocarcinomas with BilIN, 10 tubular adenocarcinomas with IPN-B and nine colloid carcinomas with IPN-B.
  • IPN-B was characterized by the intestinal phenotype (MUC2+/CK20+), and carcinogenesis leading to tubular adenocarcinoma was associated with increasing MUC1 expression and that to colloid carcinoma with MUC1-negativity.
  • Pathological stages of tubular adenocarcinoma of ICC with BilIN or IPN-B were more advanced than those of colloid carcinoma with IPN-B.
  • Increased expression of MUC1 in BilIN and also IPN-B is associated with tubular adenocarcinoma, while colloid carcinoma in IPN-B is characterized by MUC1-negativity and less advanced pathologic stages.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / pathology. Cholelithiasis / pathology. Keratins / biosynthesis. Mucins / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / biosynthesis. Diagnosis, Differential. Disease Progression. Humans. Immunohistochemistry. Neoplasm Staging. Precancerous Conditions

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallstones.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Hepatol. 2006 Feb;44(2):249-50 [16360969.001]
  • (PMID = 16360234.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


91. Chang YW, Kwon KH, Lee DW: Synchronous bilateral mucinous carcinoma of the breast: case report. Clin Imaging; 2009 Jan-Feb;33(1):62-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous bilateral mucinous carcinoma of the breast: case report.
  • A mucinous carcinoma of the breast is a well-differentiated rare histological type of invasive ductal carcinoma, having a lower frequency of metastasis to an axillary lymph node and a better survival rate.
  • Bilateral breast cancer has an overall incidence of 4% to 20% in patients with primary operable breast cancer.
  • Few reports exist in the clinical literature characterizing a synchronous bilateral mucinous carcinoma of the breast.
  • We report the characteristic imaging findings of a bilateral mucinous carcinoma of the breast.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Breast Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Mammography / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19135933.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Sugai M, Umezu H, Yamamoto T, Jiang S, Iwanari H, Tanaka T, Hamakubo T, Kodama T, Naito M: Expression of hepatocyte nuclear factor 4 alpha in primary ovarian mucinous tumors. Pathol Int; 2008 Nov;58(11):681-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte nuclear factor 4 alpha in primary ovarian mucinous tumors.
  • Ovarian mucinous adenoma, mucinous tumors of borderline malignancy, and mucinous adenocarcinoma had positive nuclear staining for HNF4 alpha (41/45, 91%).
  • One-third (34%) of mucinous tumors had P1-positive staining and most had P1/P2-positive staining (93%).
  • MUC2- and MUC5AC-positive staining was observed in 34% and 95% of mucinous tumors, respectively.
  • The histological subtype of these mucinous tumors was not correlated with HNF4 alpha expression.
  • On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha.
  • Thus, HNF4 alpha is demonstrated to be a useful marker for histological and cytological diagnosis of ovarian mucinous tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenoma, Mucinous / metabolism. Hepatocyte Nuclear Factor 4 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Ascitic Fluid / metabolism. Ascitic Fluid / pathology. Cell Nucleus / metabolism. Cell Nucleus / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Mucin 5AC. Mucin-2. Mucins / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18844932.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HNF4A protein, human; 0 / Hepatocyte Nuclear Factor 4; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


93. Ruibal A, Nuñez Cambre I, Sánchez Salmón A, Nuñez MI, Rodríguez J: [CA125 cytosolic levels in lung adenocarcinomas. New biological aspects]. Rev Esp Med Nucl; 2005 Jan-Feb;24(1):27-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CA125 cytosolic levels in lung adenocarcinomas. New biological aspects].
  • [Transliterated title] El CA125 citosólico en adenocarcinomas pulmonares. Nuevos aspectos biológicos.
  • INTRODUCTION: CA125 is a useful serum tumor marker in patients with non-mucinous ovarian cancer, but there may be high serum levels in other malignant tumors, among them the non-small cell lung cancers.
  • We decided to study the cytosolic levels of CA125 in lung adenocarcinomas and compare them with pS2, CD44s, CD44v5 and CD44v6, all of them with biological interest in this subtype of lung carcinomas.
  • SUBJECTS AND METHODS: The study group included 55 patients (33 males) having lung adenocarcinomas.
  • RESULTS: In the 55 lung adenocarcinomas, cytosolic CA125 levels ranged between 1 and 225 U/mg prot. (median 80.5) and were higher (p:0.002) than those observed in 16 normal lung tissues from the same patients (r: 1-32.5; median 6.7 U/mg prot.).
  • 1) Cytosolic CA125 levels in lung adenocarcinomas were higher than those observed in normal tissues from the same patients.
  • 2) Lung adenocarcinomas with high cytosolic CA125 concentrations had a greater positivity for CD44v6, a reduced positivity for CD44s and were more frequently pS2 +.
  • These associations support the usefulness of the cytosolic CA125 levels as an indicator of poor outcome in this subtype of lung carcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Cytosol / chemistry. Lung Neoplasms / chemistry. Proteins / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701343.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


94. Kim YN, Park SY, Kim YK, Moon WS: Xanthogranulomatous pancreatitis combined with intraductal papillary mucinous carcinoma in situ. J Korean Med Sci; 2010 Dec;25(12):1814-7
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xanthogranulomatous pancreatitis combined with intraductal papillary mucinous carcinoma in situ.
  • Xanthogranulomatous pancreatitis (XGP) associated with an intraductal papillary mucinous tumor (IPMT) is extremely rare.
  • Pylorus-preserving pancreaticoduodenectomy was performed and diagnosis of XGP combined with intraductal papillary mucinous carcinoma in situ was made.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Granuloma / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis. Xanthomatosis / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Pancreaticoduodenectomy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2004 Mar;28(3):254-7 [14961199.001]
  • [Cites] Indian J Pathol Microbiol. 2004 Jan;47(1):36-8 [15471123.001]
  • [Cites] Med Sci Monit. 2008 Nov;14(11):CS130-3 [18971878.001]
  • [Cites] AJR Am J Roentgenol. 2005 Sep;185(3):704-7 [16120922.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(2):240-2 [18392724.001]
  • [Cites] Urology. 1994 Mar;43(3):295-9 [8134982.001]
  • (PMID = 21165301.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2995240
  • [Keywords] NOTNLM ; Cystic Tumor / Pancreas / Xanthogranulomatous Inflammation
  •  go-up   go-down


95. Chaleoykitti B: Mucinous carcinoma of the colon and rectum in Phramongkutklao Hospital. J Med Assoc Thai; 2006 Jan;89(1):25-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of the colon and rectum in Phramongkutklao Hospital.
  • OBJECTIVE: The objective of the present study was to compare the clinicopathological significance between mucinous carcinoma and nonmucinous adenocarcinoma.
  • MATERIAL AND METHOD: Patients with carcinoma of the colon and rectum who had the first operation in the Department of Surgery, Phramongkutklao Hospital between 1999 and 2004 were included in the present study.
  • Patients were divided into two groups: nonmucinous group and mucinous group.
  • Forty four (10.7%) were mucinous carcinoma.
  • CONCLUSION: Colorectal mucinous carcinoma had no clinicopathological difference from nonmucinous adenocarcinoma of colon and rectum.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Colonic Neoplasms / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583577.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


96. Veras E, Srodon M, Neijstrom ES, Ronnett BM: Metastatic HPV-related cervical adenocarcinomas presenting with thromboembolic events (Trousseau Syndrome): clinicopathologic characteristics of 2 cases. Int J Gynecol Pathol; 2009 Mar;28(2):134-9
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic HPV-related cervical adenocarcinomas presenting with thromboembolic events (Trousseau Syndrome): clinicopathologic characteristics of 2 cases.
  • Two cases of systemic thromboembolism (Trousseau syndrome) associated with metastatic human papillomavirus (HPV)-related endocervical adenocarcinomas are reported.
  • Lymph node biopsy revealed metastatic mucinous adenocarcinoma with focal signet ring cell differentiation.
  • Imaging studies demonstrated metastatic disease without a defined primary site.
  • Autopsy examination revealed widespread metastatic adenocarcinoma with a 2 cm cervical adenocarcinoma.
  • Diagnostic laparoscopy with biopsies and left oophorectomy revealed metastatic mucinous adenocarcinoma with signet ring cell differentiation involving peritoneum, ovary, cervix, and bladder without a defined primary site.
  • Progressive thromboembolic disease with acute renal failure and multiple cerebral infarcts developed and the patient expired shortly after initiation of chemotherapy, 2 months after presentation.
  • High-risk HPV-related endocervical adenocarcinomas occasionally exhibit signet ring cell differentiation and can present with Trousseau syndrome.
  • These features more commonly suggest metastatic adenocarcinoma of upper gastrointestinal tract origin but the presence of HPV DNA within the tumors establishes them as cervical in origin.
  • [MeSH-major] Adenocarcinoma / complications. Papillomavirus Infections / complications. Thromboembolism / etiology. Uterine Cervical Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188822.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Iida T, Yasuda M, Miyazawa M, Fujita M, Osamura RY, Hirasawa T, Muramatsu T, Murakami M, Saito K, Mikami M: Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1alpha/GLUT-1 expression. Arch Gynecol Obstet; 2008 Jun;277(6):539-46
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1alpha/GLUT-1 expression.
  • MATERIAL AND METHODS: We analyzed the expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) by immunohistochemistry in ovarian serous and mucinous tumors from the point view of the histological characteristics and acquisition of malignancy.
  • A total of 102 ovarian tumors were examined, composed of 31 adenomas (serous 17 and mucinous 14), 32 borderline tumors (serous 13 and mucinous 19), and 39 adenocarcinomas (serous 21 and mucinous 18).
  • RESULTS: The overall positive ratios were as follows: HIF-1alpha, 74% of adenomas, 91% of borderline tumors, and 100% of adenocarcinomas; and GLUT-1, 68% of adenomas, 95% of borderline tumors, and 100% of adenocarcinomas.
  • Comparing serous tumors and mucinous tumors, there was no significant difference in the positive ratios of HIF-1alpha and GLUT-1 of adenomas, borderline tumors, and adenocarcinomas.
  • However, both markers were more strongly expressed in serous adenocarcinomas (HIF-1alpha, 3 + 100%; GLUT-1, 3+76%) than in mucinous adenocarcinomas (HIF-1alpha, 3 + 61%; GLUT-1, 3 + 28%).
  • DNA binding assay also demonstrated that HIF-1 is more commonly activated in serous adenocarcinomas than in mucinous adenocarcinomas.
  • We consider that the relatively strong expression of both markers in serous tumors compared with mucinous tumors is related to the difference in their histological characteristics.
  • [MeSH-major] Glucose Transporter Type 1 / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Neoplasms, Cystic, Mucinous, and Serous / metabolism. Neoplasms, Cystic, Mucinous, and Serous / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18026974.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Glucose Transporter Type 1; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger
  •  go-up   go-down


98. Warycha M, Kamino H, Mobini N, Hale EK: Primary mucinous carcinoma with direct histopathologic evidence of lymphatic invasion. J Drugs Dermatol; 2006 Jul-Aug;5(7):655-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous carcinoma with direct histopathologic evidence of lymphatic invasion.
  • BACKGROUND: Primary mucinous carcinoma of the skin is a rare sweat gland neoplasm which occurs most commonly in the periorbital region.
  • The standard treatment of primary mucinous carcinoma is wide local excision.
  • OBJECTIVE: We present a case of primary mucinous carcinoma arising in the scalp, which was treated with wide local excision.
  • RESULTS: Histopathologic evaluation revealed a well-circumscribed neoplasm characterized by lobules and aggregates of epithelial cells embedded in abundant pools of mucin.
  • In addition, small aggregates of neoplastic cells were found at a distance from the primary nodule, indicative of lymphatic invasion.
  • CONCLUSION: Primary mucinous carcinoma has a high propensity for locoregional metastases and recurrence.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Lymphatic Metastasis. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865872.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. D'Antonio A, Addesso M, De Dominicis G, Boscaino A, Liguori G, Nappi O: Mucinous carcinoma of thyroid gland. Report of a primary and a metastatic mucinous tumour from ovarian adenocarcinoma with immunohistochemical study and review of literature. Virchows Arch; 2007 Oct;451(4):847-51
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous carcinoma of thyroid gland. Report of a primary and a metastatic mucinous tumour from ovarian adenocarcinoma with immunohistochemical study and review of literature.
  • Mucinous carcinoma of the thyroid gland is an uncommon tumour that from the histological point of view, resembles mucinous carcinoma of others sites.
  • Although a mucinous appearance has sometimes been reported in association with cases of typical thyroid carcinoma, true mucinous carcinoma is exceptionally rare.
  • We describe two cases of thyroid tumours with mucinous differentiation studied with immunohistochemistry.
  • Both cases disclosed a similar histological appearance, with small nests and sheets of malignant epithelial cells associated with extensive extracellular mucin that substituted and entrapped the follicular parenchyma of the thyroid.
  • From these findings, we classified this tumour as primary mucinous thyroid carcinoma.
  • In this case, thyroid tumour represents the first clinical sign of an ovarian mucinous adenocarcinoma, and it has not been previously described in literature.
  • Both patients died after few months to diagnosis.
  • In conclusion, primary and secondary mucinous carcinoma are rare and unusual tumours of the thyroid gland that can be a cause of pitfall in differential diagnosis.
  • In these cases, for a correct diagnosis, a complete clinical history, restricted histological criteria and immunohistochemical panel are necessary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Ovarian Neoplasms / pathology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / secondary
  • [MeSH-minor] CA-125 Antigen / metabolism. Carcinoembryonic Antigen / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged. Nuclear Proteins / metabolism. Thyroglobulin / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704943.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 9010-34-8 / Thyroglobulin
  • [Number-of-references] 10
  •  go-up   go-down


100. Okada K, Shatari T, Sasaki T, Tamada T, Suwa T, Furuuchi T, Takenaka Y, Hori M, Sakuma M: Is histopathological evidence really essential for making a surgical decision about mucinous carcinoma arising in a perianal fistula? Report of a case. Surg Today; 2008;38(6):555-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is histopathological evidence really essential for making a surgical decision about mucinous carcinoma arising in a perianal fistula? Report of a case.
  • We report an unusual case of mucinous adenocarcinoma of the anus associated with a chronic anal fistula, treated successfully by abdominoperineal resection (APR).
  • Although multiple biopsies failed to reveal any histological evidence of malignancy, cancer was diagnosed from the mucin obtained for cytology.
  • Subsequent histological examination of the resected specimen revealed clusters of cancer cells floating in a mucous lake, suggesting that it would have been difficult to acquire the cells in a biopsy sample.
  • Conversely, the presence of mucin lakes and globules in specimens drained from the region of perianal sepsis may have been histologically informative for diagnosis.
  • Thus, although biopsy of the lesion is undoubtedly essential for diagnosis, it often fails to provide enough information to make a definite diagnosis of mucinous carcinoma.
  • This case illustrates that clinicians should base their decision on whether to perform surgery on clinical manifestations, imaging findings, and cytology of mucin obtained by drainage when it is difficult to obtain malignant cells by biopsy.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Anus Neoplasms / pathology. Anus Neoplasms / surgery. Rectal Fistula / complications

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516539.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement